CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | nitrogen atom |
|
Accession: | CHEBI:25555
|
browse the term
|
Synonyms: | related_synonym: | 7N; Formula=N; N; Stickstoff; azote; nitrogen; nitrogeno |
| xref: | WebElements:N |
|
|
|
G |
NPPA |
natriuretic peptide A |
affects abundance |
EXP |
NPPA protein affects the abundance of Epinephrine |
CTD |
PMID:2951327 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
increases activity |
EXP |
Norepinephrine results in increased activity of ADRB1 protein |
CTD |
PMID:10344530 |
|
NCBI chr28:24,908,224...24,909,684
Ensembl chr28:24,908,224...24,909,684
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions |
EXP |
[Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased secretion of Norepinephrine |
CTD |
PMID:2884805 |
|
NCBI chr 4:60,048,502...60,050,447
Ensembl chr 4:59,941,517...60,050,298
|
|
G |
NPPA |
natriuretic peptide A |
increases expression |
EXP |
Norepinephrine results in increased expression of NPPA protein |
CTD |
PMID:8952593 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions increases activity |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein]; [Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
POMC |
proopiomelanocortin |
increases response to substance |
EXP |
POMC protein results in increased susceptibility to Norepinephrine |
CTD |
PMID:6279499 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
G |
REN |
renin |
increases activity |
EXP |
Norepinephrine results in increased activity of REN protein |
CTD |
PMID:8952593 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
PLCG1 |
phospholipase C gamma 1 |
decreases activity multiple interactions |
EXP |
1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein dipalmitoylphosphatidic acid inhibits the reaction [1,2-Dipalmitoylphosphatidylcholine results in decreased activity of PLCG1 protein] |
CTD |
PMID:2001791 |
|
NCBI chr24:29,198,536...29,213,899
Ensembl chr24:29,198,556...29,214,714
|
|
|
G |
CASP8 |
caspase 8 |
increases activity multiple interactions |
EXP |
4-phenylenediamine results in increased activity of CASP8 protein benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [4-phenylenediamine results in increased activity of CASP8 protein] |
CTD |
PMID:20156547 |
|
NCBI chr37:10,362,071...10,402,108
Ensembl chr37:10,391,048...10,401,822
|
|
G |
CASP9 |
caspase 9 |
multiple interactions increases activity |
EXP |
benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone inhibits the reaction [4-phenylenediamine results in increased activity of CASP9 protein] |
CTD |
PMID:20156547 |
|
NCBI chr 2:82,033,759...82,076,710
Ensembl chr 2:82,031,563...82,090,484
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[Verapamil results in decreased activity of ABCB1 protein] which affects the transport of Digoxin |
CTD |
PMID:20510202 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
P2RY2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP |
[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:10604969 |
|
NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
|
|
|
G |
CDIPT |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
EXP |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein |
CTD |
PMID:15161604 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Cisapride binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:12388285 |
|
NCBI chr16:15,009,031...15,041,786
Ensembl chr16:15,009,031...15,041,504
|
|
|
G |
ALPI |
alkaline phosphatase, intestinal |
increases chemical synthesis |
EXP |
ALPI protein results in increased chemical synthesis of nitrophenylphosphate |
CTD |
PMID:1495895 |
|
NCBI chr25:44,107,418...44,110,947
|
|
|
G |
P2RY2 |
purinergic receptor P2Y2 |
multiple interactions |
EXP |
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Arachidonic Acid]; pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid inhibits the reaction [[Uridine Triphosphate results in increased activity of P2RY2 protein] which results in increased abundance of Cyclic AMP] |
CTD |
PMID:10604969 |
|
NCBI chr21:24,987,568...25,009,754
Ensembl chr21:24,992,848...24,996,059
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Omeprazole results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
decreases activity |
EXP |
5-nitro-2-(3-phenylpropylamino)benzoic acid results in decreased activity of CFTR protein |
CTD |
PMID:15496164 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
increases activity |
EXP |
6-(4-chlorophenyl)imidazo(2,1-b)(1,3)thiazole-5-carbaldehyde O-(3,4-dichlorobenzyl)oxime results in increased activity of NR1I3 protein mutant form |
CTD |
PMID:21778469 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
ATP6V0D1 |
ATPase H+ transporting V0 subunit d1 |
increases expression |
EXP |
Uric Acid results in increased expression of ATP6V0D1 protein |
CTD |
PMID:32991862 |
|
NCBI chr 5:81,926,589...81,965,959
Ensembl chr 5:81,926,612...81,965,526
|
|
G |
DNAJC3 |
DnaJ heat shock protein family (Hsp40) member C3 |
increases expression |
EXP |
Uric Acid results in increased expression of DNAJC3 protein |
CTD |
PMID:32991862 |
|
NCBI chr22:46,323,263...46,402,240
Ensembl chr22:46,307,905...46,398,625
|
|
G |
EEF2 |
eukaryotic translation elongation factor 2 |
decreases expression |
EXP |
Uric Acid results in decreased expression of EEF2 protein |
CTD |
PMID:32991862 |
|
NCBI chr20:55,577,413...55,586,422
Ensembl chr20:55,522,213...55,586,126
|
|
G |
EZR |
ezrin |
increases expression |
EXP |
Uric Acid results in increased expression of EZR protein |
CTD |
PMID:32991862 |
|
NCBI chr 1:48,160,206...48,210,036
Ensembl chr 1:48,160,206...48,210,036
|
|
G |
HNRNPA2B1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
increases expression |
EXP |
Uric Acid results in increased expression of HNRNPA2B1 protein |
CTD |
PMID:32991862 |
|
NCBI chr14:39,498,805...39,509,034
Ensembl chr14:39,500,897...39,508,952
|
|
G |
HSP90AA1 |
heat shock protein 90 alpha family class A member 1 |
increases expression |
EXP |
Uric Acid results in increased expression of HSP90AA1 protein |
CTD |
PMID:32991862 |
|
NCBI chr 8:70,091,203...70,096,107
Ensembl chr 8:70,092,217...70,095,243
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Uric Acid results in increased expression of HSPA5 protein |
CTD |
PMID:32991862 |
|
NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
|
|
G |
HSPD1 |
heat shock protein family D (Hsp60) member 1 |
decreases expression |
EXP |
Uric Acid results in decreased expression of HSPD1 protein |
CTD |
PMID:32991862 |
|
NCBI chr37:7,010,421...7,025,912
|
|
G |
IMMT |
inner membrane mitochondrial protein |
increases expression |
EXP |
Uric Acid results in increased expression of IMMT protein |
CTD |
PMID:32991862 |
|
NCBI chr17:38,927,508...38,964,522
Ensembl chr17:38,927,531...38,967,004
|
|
G |
LOC102151342 |
ATP synthase subunit d, mitochondrial-like |
increases expression |
EXP |
Uric Acid results in increased expression of ATP5PD protein |
CTD |
PMID:32991862 |
|
NCBI chr 7:66,856,651...66,857,162
|
|
G |
MDH2 |
malate dehydrogenase 2 |
decreases expression |
EXP |
Uric Acid results in decreased expression of MDH2 protein |
CTD |
PMID:32991862 |
|
NCBI chr 6:7,389,266...7,405,311
|
|
G |
NAPA |
NSF attachment protein alpha |
decreases expression |
EXP |
Uric Acid results in decreased expression of NAPA protein |
CTD |
PMID:32991862 |
|
NCBI chr 1:108,510,920...108,533,317
Ensembl chr 1:108,510,931...108,532,881
|
|
G |
OAT |
ornithine aminotransferase |
increases expression |
EXP |
Uric Acid results in increased expression of OAT protein |
CTD |
PMID:32991862 |
|
NCBI chr28:33,763,661...33,788,817
Ensembl chr28:33,758,473...33,788,759
|
|
G |
PC |
pyruvate carboxylase |
decreases expression |
EXP |
Uric Acid results in decreased expression of PC protein |
CTD |
PMID:32991862 |
|
NCBI chr18:50,406,994...50,507,677
Ensembl chr18:50,412,272...50,507,669
|
|
G |
RAB11A |
RAB11A, member RAS oncogene family |
decreases expression |
EXP |
Uric Acid results in decreased expression of RAB11A protein |
CTD |
PMID:32991862 |
|
NCBI chr30:30,200,831...30,218,412
Ensembl chr30:30,200,831...30,218,411
|
|
G |
SAE1 |
SUMO1 activating enzyme subunit 1 |
decreases expression |
EXP |
Uric Acid results in decreased expression of SAE1 protein |
CTD |
PMID:32991862 |
|
NCBI chr 1:108,757,543...108,864,763
Ensembl chr 1:108,749,061...108,859,797
|
|
G |
SLC25A12 |
solute carrier family 25 member 12 |
decreases expression |
EXP |
Uric Acid results in decreased expression of SLC25A12 protein |
CTD |
PMID:32991862 |
|
NCBI chr36:16,185,011...16,391,080
Ensembl chr36:16,185,649...16,483,016
|
|
G |
SLC2A9 |
solute carrier family 2 member 9 |
increases transport |
EXP |
SLC2A9 protein results in increased transport of Uric Acid |
CTD |
PMID:18989453 |
|
NCBI chr 3:69,394,304...69,588,462
Ensembl chr 3:69,394,152...69,595,802
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
multiple interactions |
EXP |
[1-Methyl-3-isobutylxanthine co-treated with 8-((4-chlorophenyl)thio)cyclic-3',5'-AMP] results in increased activity of CFTR protein |
CTD |
PMID:15161604 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
KCNJ3 |
potassium inwardly rectifying channel subfamily J member 3 |
multiple interactions |
EXP |
Acetylcholine promotes the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium] |
CTD |
PMID:10666054 |
|
NCBI chr36:1,354,686...1,496,397
Ensembl chr36:1,354,678...1,493,766
|
|
G |
KCNJ6 |
potassium inwardly rectifying channel subfamily J member 6 |
multiple interactions |
EXP |
Acetylcholine promotes the reaction [[KCNJ3 protein co-treated with KCNJ6 protein] results in increased transport of Potassium] |
CTD |
PMID:10666054 |
|
NCBI chr31:32,752,585...33,010,999
Ensembl chr31:32,755,899...32,934,478
|
|
G |
MAPK14 |
mitogen-activated protein kinase 14 |
multiple interactions |
EXP |
Acetylcholine results in increased phosphorylation of and results in increased activity of MAPK14 protein |
CTD |
PMID:9688607 |
|
NCBI chr12:5,145,647...5,221,558
Ensembl chr12:5,146,037...5,220,603
|
|
|
G |
AVP |
arginine vasopressin |
decreases activity |
EXP |
Acyclovir results in decreased activity of AVP protein |
CTD |
PMID:2724137 |
|
NCBI chr24:18,183,057...18,184,827
Ensembl chr24:18,183,057...18,184,883
|
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
decreases activity |
EXP |
Amiodarone results in decreased activity of SLC8A1 protein |
CTD |
PMID:15288574 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
REN |
renin |
increases expression |
EXP |
Amlodipine results in increased expression of REN protein |
CTD |
PMID:10218729 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ADRB1 |
adrenoceptor beta 1 |
multiple interactions |
EXP |
amosulalol binds to and results in decreased activity of ADRB1 protein |
CTD |
PMID:6129981 |
|
NCBI chr28:24,908,224...24,909,684
Ensembl chr28:24,908,224...24,909,684
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions |
EXP |
amosulalol binds to and results in decreased activity of ADRB2 protein |
CTD |
PMID:6129981 |
|
NCBI chr 4:60,048,502...60,050,447
Ensembl chr 4:59,941,517...60,050,298
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Sodium Chloride promotes the reaction [SP1 protein binds to JUN protein]] |
CTD |
PMID:23816505 |
|
NCBI chr 5:50,966,698...50,968,939
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
G |
SP1 |
Sp1 transcription factor |
multiple interactions |
EXP |
pyrazolanthrone inhibits the reaction [Sodium Chloride promotes the reaction [SP1 protein binds to JUN protein]]; pyrazolanthrone inhibits the reaction [Sodium Chloride results in increased expression of SP1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr27:1,802,587...1,861,187
Ensembl chr27:1,805,184...1,847,226
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Antipyrine results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Astemizole binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:12388285 |
|
NCBI chr16:15,009,031...15,041,786
Ensembl chr16:15,009,031...15,041,504
|
|
|
G |
REN |
renin |
multiple interactions |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ACHE |
acetylcholinesterase |
multiple interactions |
EXP |
[Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Sarin results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [Soman results in decreased activity of ACHE protein]; [Obidoxime Chloride co-treated with Atropine] inhibits the reaction [VX results in decreased activity of ACHE protein] |
CTD |
PMID:16915560 |
|
NCBI chr 6:8,874,747...8,879,926
Ensembl chr 6:8,873,584...8,879,702
|
|
G |
SCT |
secretin |
multiple interactions |
EXP |
Atropine inhibits the reaction [SCT protein results in increased abundance of Bicarbonates] |
CTD |
PMID:3562434 |
|
|
|
|
G |
CDH1 |
cadherin 1 |
decreases uptake |
EXP |
azaspiracid results in decreased uptake of CDH1 protein modified form |
CTD |
PMID:20547569 |
|
NCBI chr 5:80,757,508...80,834,878
Ensembl chr 5:80,757,508...80,834,878
|
|
|
G |
DES |
desmin |
decreases expression |
EXP |
benazepril results in decreased expression of DES mRNA |
CTD |
PMID:20137276 |
|
NCBI chr37:25,933,525...25,939,910
Ensembl chr37:25,933,455...25,940,985
|
|
|
G |
ABCB11 |
ATP binding cassette subfamily B member 11 |
decreases localization |
EXP |
blebbistatin results in decreased localization of ABCB11 protein |
CTD |
PMID:15826951 |
|
NCBI chr36:13,742,895...13,835,312
Ensembl chr36:13,746,964...13,834,974
|
|
|
G |
BCHE |
butyrylcholinesterase |
increases hydrolysis multiple interactions |
EXP |
BCHE protein results in increased hydrolysis of butyrylcholine Succinylcholine inhibits the reaction [BCHE protein results in increased hydrolysis of butyrylcholine] |
CTD |
PMID:4631366 PMID:4985882 |
|
NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
|
|
|
G |
BCHE |
butyrylcholinesterase |
increases hydrolysis |
EXP |
BCHE protein results in increased hydrolysis of Butyrylthiocholine |
CTD |
PMID:22407886 |
|
NCBI chr34:30,912,632...30,977,624
Ensembl chr34:30,912,632...30,977,583
|
|
|
G |
HTR1B |
5-hydroxytryptamine receptor 1B |
multiple interactions |
EXP |
HTR1B protein promotes the reaction [donitriptan results in decreased susceptibility to Capsaicin] |
CTD |
PMID:16880765 |
|
NCBI chr12:38,659,088...38,659,546
|
|
G |
TRPV1 |
transient receptor potential cation channel subfamily V member 1 |
multiple interactions increases activity |
EXP |
JYL 1421 inhibits the reaction [Capsaicin results in increased activity of TRPV1 protein] |
CTD |
PMID:17392452 |
|
NCBI chr 9:47,404,987...47,443,871
Ensembl chr 9:47,404,972...47,431,926
|
|
|
G |
MGMT |
O-6-methylguanine-DNA methyltransferase |
decreases response to substance multiple interactions |
EXP |
MGMT protein mutant form results in decreased susceptibility to Carmustine; MGMT protein results in decreased susceptibility to Carmustine MGMT protein mutant form results in decreased susceptibility to [Carmustine co-treated with O(6)-benzylguanine] |
CTD |
PMID:14617759 PMID:15053863 |
|
NCBI chr28:38,204,611...38,427,482
Ensembl chr28:38,204,610...38,427,380
|
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
carprofen results in decreased expression of PTGS2 mRNA |
CTD |
PMID:15198222 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
|
G |
CASP3 |
caspase 3 |
decreases activity |
EXP |
Carvedilol results in decreased activity of CASP3 protein |
CTD |
PMID:12875697 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
G |
FAS |
Fas cell surface death receptor |
decreases expression |
EXP |
Carvedilol results in decreased expression of FAS |
CTD |
PMID:12875697 |
|
NCBI chr26:38,738,811...38,763,298
Ensembl chr26:38,737,611...38,763,321
|
|
G |
FASLG |
Fas ligand |
decreases expression |
EXP |
Carvedilol results in decreased expression of FASLG |
CTD |
PMID:12875697 |
|
NCBI chr 7:26,335,837...26,344,224
Ensembl chr 7:26,335,846...26,344,224
|
|
G |
NT5E |
5'-nucleotidase ecto |
increases activity |
EXP |
Carvedilol results in increased activity of NT5E protein |
CTD |
PMID:15148268 |
|
NCBI chr12:45,491,028...45,520,019
Ensembl chr12:45,491,733...45,518,405
|
|
G |
RYR2 |
ryanodine receptor 2 |
multiple interactions |
EXP |
Carvedilol results in decreased oxidation of and results in increased stability of RYR2 protein |
CTD |
PMID:17448375 |
|
NCBI chr 4:2,371,868...2,908,132
Ensembl chr 4:2,373,114...2,907,875
|
|
|
G |
ACE |
angiotensin I converting enzyme |
decreases activity |
EXP |
ceronapril results in decreased activity of ACE protein |
CTD |
PMID:1812274 |
|
NCBI chr 9:11,497,182...11,516,362
Ensembl chr 9:11,497,182...11,516,358
|
|
|
G |
SCT |
secretin |
multiple interactions |
EXP |
[Ceruletide co-treated with SCT protein] results in increased abundance of Bicarbonates |
CTD |
PMID:3562434 |
|
|
|
|
G |
AGT |
angiotensinogen |
decreases expression |
EXP |
Cilazapril results in decreased expression of AGT protein |
CTD |
PMID:2419701 |
|
NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
|
|
G |
REN |
renin |
increases activity |
EXP |
Cilazapril results in increased activity of REN protein |
CTD |
PMID:2419701 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
MYC |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
EXP |
Cilostazol results in decreased expression of MYC mRNA |
CTD |
PMID:19545562 |
|
NCBI chr13:25,200,772...25,205,309
Ensembl chr13:25,200,577...25,205,309
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
decreases activity |
EXP |
Cimetidine results in decreased activity of SLC22A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
|
|
|
G |
KCNH2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
EXP |
Cisapride binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:12388285 |
|
NCBI chr16:15,009,031...15,041,786
Ensembl chr16:15,009,031...15,041,504
|
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
multiple interactions increases response to substance |
EXP |
Clonidine binds to and results in increased activity of ADRA2A protein ADRA2A protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr28:22,366,989...22,392,163
Ensembl chr28:22,367,780...22,370,684
|
|
G |
ADRA2C |
adrenoceptor alpha 2C |
increases response to substance |
EXP |
ADRA2C protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr 3:60,608,632...60,648,112
Ensembl chr 3:60,646,132...60,647,722
|
|
G |
GH1 |
growth hormone |
increases secretion |
EXP |
Clonidine results in increased secretion of GH1 protein |
CTD |
PMID:6248808 |
|
NCBI chr 9:11,832,265...11,834,123
Ensembl chr 9:11,832,265...11,834,123
|
|
G |
NISCH |
nischarin |
multiple interactions affects binding |
EXP |
Guanine Nucleotides inhibits the reaction [Clonidine binds to NISCH protein] |
CTD |
PMID:24120658 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions increases activity |
EXP |
[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein] |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
G |
REN |
renin |
multiple interactions decreases activity |
EXP |
Clonidine results in decreased secretion of and results in decreased activity of REN protein Clonidine results in decreased activity of REN protein |
CTD |
PMID:6248808 PMID:6991409 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
multiple interactions increases response to substance |
EXP |
Clonidine binds to and results in increased activity of ADRA2A protein ADRA2A protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr28:22,366,989...22,392,163
Ensembl chr28:22,367,780...22,370,684
|
|
G |
ADRA2C |
adrenoceptor alpha 2C |
increases response to substance |
EXP |
ADRA2C protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr 3:60,608,632...60,648,112
Ensembl chr 3:60,646,132...60,647,722
|
|
G |
GH1 |
growth hormone |
increases secretion |
EXP |
Clonidine results in increased secretion of GH1 protein |
CTD |
PMID:6248808 |
|
NCBI chr 9:11,832,265...11,834,123
Ensembl chr 9:11,832,265...11,834,123
|
|
G |
NISCH |
nischarin |
affects binding multiple interactions |
EXP |
Clonidine binds to NISCH protein Guanine Nucleotides inhibits the reaction [Clonidine binds to NISCH protein] |
CTD |
PMID:24120658 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
increases activity multiple interactions |
EXP |
Clonidine results in increased activity of PIK3CG protein [Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein] |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
G |
REN |
renin |
multiple interactions decreases activity |
EXP |
Clonidine results in decreased secretion of and results in decreased activity of REN protein Clonidine results in decreased activity of REN protein |
CTD |
PMID:6248808 PMID:6991409 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ADRA2A |
adrenoceptor alpha 2A |
multiple interactions increases response to substance |
EXP |
Clonidine binds to and results in increased activity of ADRA2A protein ADRA2A protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr28:22,366,989...22,392,163
Ensembl chr28:22,367,780...22,370,684
|
|
G |
ADRA2C |
adrenoceptor alpha 2C |
increases response to substance |
EXP |
ADRA2C protein results in increased susceptibility to Clonidine |
CTD |
PMID:16814767 |
|
NCBI chr 3:60,608,632...60,648,112
Ensembl chr 3:60,646,132...60,647,722
|
|
G |
GH1 |
growth hormone |
increases secretion |
EXP |
Clonidine results in increased secretion of GH1 protein |
CTD |
PMID:6248808 |
|
NCBI chr 9:11,832,265...11,834,123
Ensembl chr 9:11,832,265...11,834,123
|
|
G |
NISCH |
nischarin |
affects binding multiple interactions |
EXP |
Clonidine binds to NISCH protein Guanine Nucleotides inhibits the reaction [Clonidine binds to NISCH protein] |
CTD |
PMID:24120658 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions increases activity |
EXP |
[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate; Yohimbine inhibits the reaction [[Clonidine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; Yohimbine inhibits the reaction [Clonidine results in increased activity of PIK3CG protein] |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions increases phosphorylation |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; Yohimbine inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
G |
REN |
renin |
multiple interactions decreases activity |
EXP |
Clonidine results in decreased secretion of and results in decreased activity of REN protein Clonidine results in decreased activity of REN protein |
CTD |
PMID:6248808 PMID:6991409 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Clotrimazole results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
affects binding increases activity |
EXP |
Clotrimazole binds to NR1I3 protein Clotrimazole results in increased activity of NR1I3 protein; Clotrimazole results in increased activity of NR1I3 protein mutant form |
CTD |
PMID:21778469 PMID:27732639 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
INS |
insulin |
increases abundance |
EXP |
INS protein results in increased abundance of Adrenocorticotropic Hormone |
CTD |
PMID:1646414 |
|
NCBI chr18:46,324,047...46,324,933
Ensembl chr18:46,324,041...46,325,122
|
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases hydroxylation |
EXP |
CYP2B6 protein results in increased hydroxylation of Cyclophosphamide |
CTD |
PMID:16546968 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
|
G |
CDIPT |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
EXP |
[delta-hexachlorocyclohexane results in decreased activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Hexachlorocyclohexane affects the activity of CDIPT protein] which results in decreased abundance of Cytidine Monophosphate; [Inositol promotes the reaction [CDIPT protein results in increased metabolism of Cytidine Diphosphate Diglycerides]] which results in increased abundance of Cytidine Monophosphate |
CTD |
PMID:2579070 |
|
NCBI chr 6:17,910,141...17,914,573
Ensembl chr 6:17,910,192...17,914,653
|
|
|
G |
AGT |
angiotensinogen |
multiple interactions |
EXP |
Deferoxamine inhibits the reaction [AGT protein modified form results in increased susceptibility to Serotonin] |
CTD |
PMID:8021468 |
|
NCBI chr 4:8,681,192...8,694,059
Ensembl chr 4:8,683,798...8,693,880
|
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D15 affects the metabolism of Desipramine |
CTD |
PMID:7786018 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
|
G |
NISCH |
nischarin |
affects activity |
EXP |
Dexmedetomidine affects the activity of NISCH |
CTD |
PMID:7486159 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases metabolic processing |
EXP |
CYP2B6 protein results in increased metabolism of Dextromethorphan |
CTD |
PMID:12637241 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D15 affects the metabolism of Dextromethorphan |
CTD |
PMID:7786018 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
|
G |
CYP2C18 |
cytochrome P450 2C21 |
affects metabolic processing |
EXP |
CYP2C19 protein affects the metabolism of Diazepam |
CTD |
PMID:15801540 |
|
NCBI chr28:8,727,010...8,750,427
Ensembl chr28:8,727,019...8,750,587
|
|
G |
CYP3A12 |
cytochrome P-450 3A12 |
multiple interactions increases hydroxylation |
EXP |
Ketoconazole inhibits the reaction [CYP3A12 protein results in increased hydroxylation of Diazepam] |
CTD |
PMID:15677349 |
|
|
|
|
G |
CYP2C18 |
cytochrome P450 2C21 |
increases hydroxylation |
EXP |
CYP2C19 protein results in increased hydroxylation of Diclofenac |
CTD |
PMID:15677349 |
|
NCBI chr28:8,727,010...8,750,427
Ensembl chr28:8,727,019...8,750,587
|
|
G |
CYP2C41 |
cytochrome P450 2C41 |
affects metabolic processing |
EXP |
CYP2C9 protein affects the metabolism of Diclofenac |
CTD |
PMID:15801540 |
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Diclofenac results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
Ditiocarb inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene] |
CTD |
PMID:8592870 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
|
G |
SLCO1B2 |
solute carrier organic anion transporter family member 1B2 |
increases transport |
EXP |
SLCO1B3 protein results in increased transport of Enkephalin, D-Penicillamine (2,5)- |
CTD |
PMID:20079461 |
|
NCBI chr27:26,411,008...26,496,174
Ensembl chr27:26,411,010...26,470,989
|
|
|
G |
SELP |
selectin P |
decreases expression |
EXP |
Edaravone results in decreased expression of SELP protein |
CTD |
PMID:16041266 |
|
NCBI chr 7:28,956,428...28,997,266
Ensembl chr 7:28,958,486...28,996,313
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance |
EXP |
ABCB1 protein affects the susceptibility to emodepside |
CTD |
PMID:25660379 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of ATP2A2 protein |
CTD |
PMID:18820026 |
|
NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of EGR1 protein |
CTD |
PMID:18820026 |
|
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of GATA4 protein |
CTD |
PMID:18820026 |
|
NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
|
|
G |
KCND3 |
potassium voltage-gated channel subfamily D member 3 |
decreases expression |
EXP |
Enalapril results in decreased expression of KCND3 mRNA |
CTD |
PMID:19732978 |
|
NCBI chr17:63,470,829...63,668,354
Ensembl chr17:63,470,415...63,668,035
|
|
G |
NAB1 |
NGFI-A binding protein 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of NAB1 protein |
CTD |
PMID:18820026 |
|
NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
|
|
G |
NOS3 |
nitric oxide synthase 3 |
multiple interactions increases expression |
EXP |
FR 173657 inhibits the reaction [Enalapril results in increased expression of NOS3 mRNA] |
CTD |
PMID:12019275 |
|
NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
|
|
G |
NPPA |
natriuretic peptide A |
decreases expression multiple interactions |
EXP |
Enalapril results in decreased expression of NPPA protein FR 173657 inhibits the reaction [Enalapril results in decreased expression of NPPA protein] |
CTD |
PMID:12019275 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
G |
REN |
renin |
increases activity multiple interactions |
EXP |
Enalapril results in increased activity of REN protein [Enalapril co-treated with FR 173657] results in increased activity of REN protein |
CTD |
PMID:12019275 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of SLC8A1 protein |
CTD |
PMID:18820026 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Felodipine results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
|
G |
EDN1 |
endothelin 1 |
increases activity |
EXP |
Fenfluramine results in increased activity of EDN1 protein |
CTD |
PMID:9918753 |
|
NCBI chr35:11,808,892...11,815,383
Ensembl chr35:11,808,892...11,815,383
|
|
|
G |
CPNE6 |
copine 6 |
decreases activity |
EXP |
Flufenamic Acid results in decreased activity of DHRS4 protein |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
multiple interactions |
EXP |
Fomepizole inhibits the reaction [CYP2E1 protein affects the metabolism of Toluene] |
CTD |
PMID:8592870 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
|
G |
GNAQ |
G protein subunit alpha q |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein] |
CTD |
PMID:21671308 |
|
NCBI chr 1:80,733,530...80,928,065
Ensembl chr 1:80,715,366...80,928,065
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; G(M1) Ganglioside inhibits the reaction [Melitten results in increased secretion of HEXB protein]; G(M1) Ganglioside inhibits the reaction [Wasp Venoms results in increased secretion of HEXB protein] |
CTD |
PMID:21334356 PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Glutathione inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Glutathione inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
|
G |
CFTR |
CF transmembrane conductance regulator |
decreases activity |
EXP |
Glyburide results in decreased activity of CFTR protein |
CTD |
PMID:15496164 |
|
NCBI chr14:56,290,417...56,452,919
Ensembl chr14:56,290,275...56,453,977
|
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
decreases activity |
EXP |
hexaconazole results in decreased activity of SLC47A1 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
decreases activity |
EXP |
hexaconazole results in decreased activity of SLC47A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
|
|
|
G |
NISCH |
nischarin |
multiple interactions |
EXP |
Idazoxan binds to and results in decreased activity of NISCH protein |
CTD |
PMID:8732285 |
|
NCBI chr20:37,278,660...37,312,549
Ensembl chr20:37,279,282...37,312,636
|
|
|
G |
NR1I3 |
nuclear receptor subfamily 1 group I member 3 |
decreases activity multiple interactions |
EXP |
Imidazoles results in decreased activity of NR1I3 protein alternative form artemisinin inhibits the reaction [Imidazoles results in decreased activity of NR1I3 protein alternative form]; Imidazoles inhibits the reaction [artemisinin results in increased activity of NR1I3 protein mutant form] |
CTD |
PMID:21778469 |
|
NCBI chr38:21,252,874...21,257,951
Ensembl chr38:21,253,089...21,258,827
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Indomethacin results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican; [Pantoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
[iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein |
CTD |
PMID:24389113 |
|
NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
[iprodione binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein |
CTD |
PMID:24389113 |
|
NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
|
|
|
G |
CPNE6 |
copine 6 |
increases reduction |
EXP |
DHRS4 protein results in increased reduction of Isatin |
CTD |
PMID:17827741 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
|
G |
REN |
renin |
multiple interactions increases activity |
EXP |
Atenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Pindolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Propranolol inhibits the reaction [Isoproterenol results in increased activity of REN protein]; xibenolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
decreases expression multiple interactions decreases activity |
EXP |
Ketoconazole results in decreased expression of ABCB1 mRNA [Ketoconazole results in decreased activity of ABCB1 protein] which results in decreased transport of Technetium Tc 99m Sestamibi |
CTD |
PMID:19754906 PMID:22620706 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
CYP3A12 |
cytochrome P-450 3A12 |
multiple interactions decreases activity |
EXP |
Ketoconazole inhibits the reaction [CYP3A12 protein results in increased hydroxylation of Diazepam] Ketoconazole results in decreased activity of CYP3A12 protein |
CTD |
PMID:15677349 |
|
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Lansoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
affects response to substance increases export |
EXP |
ABCB1 protein affects the susceptibility to Loperamide ABCB1 protein results in increased export of Loperamide |
CTD |
PMID:25660379 PMID:28093773 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
CASP3 |
caspase 3 |
increases activity |
EXP |
Loratadine results in increased activity of CASP3 protein |
CTD |
PMID:20570632 |
|
NCBI chr16:45,920,074...45,940,507
Ensembl chr16:45,920,071...45,940,505
|
|
|
G |
REN |
renin |
increases expression |
EXP |
Losartan results in increased expression of REN protein |
CTD |
PMID:10483973 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
REN |
renin |
increases expression |
EXP |
losartan carboxylic acid results in increased expression of REN protein |
CTD |
PMID:10483973 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
PIK3CG |
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Norepinephrine results in increased activity of PIK3CG protein] which results in increased chemical synthesis of phosphatidylinositol 3-phosphate]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of PIK3CG protein] |
CTD |
PMID:15958164 |
|
NCBI chr18:13,576,966...13,611,748
Ensembl chr18:13,570,999...13,611,141
|
|
G |
PRKCZ |
protein kinase C zeta |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Clonidine results in increased phosphorylation of PRKCZ protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKCZ protein] |
CTD |
PMID:15958164 |
|
NCBI chr 5:57,012,020...57,113,346
Ensembl chr 5:57,012,070...57,112,664
|
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of CASP8 mRNA] |
CTD |
PMID:31005593 |
|
NCBI chr37:10,362,071...10,402,108
Ensembl chr37:10,391,048...10,401,822
|
|
G |
FADD |
Fas associated via death domain |
increases expression |
EXP |
marbofloxacin results in increased expression of FADD mRNA |
CTD |
PMID:31005593 |
|
NCBI chr18:48,087,447...48,094,497
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
EXP |
marbofloxacin results in increased expression of TNF mRNA; marbofloxacin results in increased expression of TNF protein |
CTD |
PMID:31005593 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of CASP8 mRNA]; TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of TRADD mRNA] marbofloxacin results in increased expression of TNFRSF1A mRNA; marbofloxacin results in increased expression of TNFRSF1A protein |
CTD |
PMID:31005593 |
|
NCBI chr27:38,641,837...38,654,693
Ensembl chr27:38,638,753...38,700,282
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
multiple interactions increases expression |
EXP |
TNFRSF1A mRNA promotes the reaction [marbofloxacin results in increased expression of TRADD mRNA] |
CTD |
PMID:31005593 |
|
NCBI chr 5:82,200,430...82,211,430
Ensembl chr 5:82,206,111...82,210,963
|
|
|
G |
ABCA5 |
ATP binding cassette subfamily A member 5 |
increases expression |
EXP |
masitinib results in increased expression of ABCA5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:15,708,070...15,781,100
Ensembl chr 9:15,420,835...15,783,045
|
|
G |
ABHD14A |
abhydrolase domain containing 14A |
increases expression |
EXP |
masitinib results in increased expression of ABHD14A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:37,738,500...37,744,689
|
|
G |
ABITRAM |
actin binding transcription modulator |
decreases expression |
EXP |
masitinib results in decreased expression of ABITRAM mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:64,094,653...64,100,078
Ensembl chr11:64,094,721...64,109,421
|
|
G |
ABLIM1 |
actin binding LIM protein 1 |
increases expression |
EXP |
masitinib results in increased expression of ABLIM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:25,260,323...25,543,369
Ensembl chr28:25,260,873...25,545,304
|
|
G |
ACAT2 |
acetyl-CoA acetyltransferase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of ACAT2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:49,011,665...49,029,368
Ensembl chr 1:49,011,706...49,029,327
|
|
G |
ACSM3 |
acyl-CoA synthetase medium chain family member 3 |
increases expression |
EXP |
masitinib results in increased expression of ACSM3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:24,558,010...24,594,326
Ensembl chr 6:24,558,142...24,582,728
|
|
G |
ACTL7A |
actin like 7A |
increases expression |
EXP |
masitinib results in increased expression of ACTL7A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:64,031,305...64,033,908
Ensembl chr11:64,032,358...64,033,788
|
|
G |
ACTR2 |
actin related protein 2 |
decreases expression |
EXP |
masitinib results in decreased expression of ACTR2 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:64,696,068...64,733,027
Ensembl chr10:64,696,111...64,730,553
|
|
G |
ADPRH |
ADP-ribosylarginine hydrolase |
increases expression |
EXP |
masitinib results in increased expression of ADPRH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr33:23,218,633...23,226,844
Ensembl chr33:23,218,101...23,224,667
|
|
G |
AGA |
aspartylglucosaminidase |
increases expression |
EXP |
masitinib results in increased expression of AGA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:52,314,860...52,324,879
Ensembl chr16:52,314,535...52,324,894
|
|
G |
AGO2 |
argonaute RISC catalytic component 2 |
decreases expression |
EXP |
masitinib results in decreased expression of AGO2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:35,169,243...35,230,252
Ensembl chr13:35,180,912...35,268,577
|
|
G |
AGRN |
agrin |
increases expression |
EXP |
masitinib results in increased expression of AGRN mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:56,239,621...56,273,679
Ensembl chr 5:56,239,701...56,272,745
|
|
G |
AIG1 |
androgen induced 1 |
increases expression |
EXP |
masitinib results in increased expression of AIG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:34,643,994...34,884,445
Ensembl chr 1:34,643,764...34,884,119
|
|
G |
ALAS2 |
5'-aminolevulinate synthase 2 |
increases expression |
EXP |
masitinib results in increased expression of ALAS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:46,703,477...46,731,767
Ensembl chr X:46,703,477...46,723,529
|
|
G |
ALDH5A1 |
aldehyde dehydrogenase 5 family member A1 |
decreases expression |
EXP |
masitinib results in decreased expression of ALDH5A1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr35:22,560,005...22,590,996
Ensembl chr35:22,560,008...22,587,875
|
|
G |
AMN1 |
antagonist of mitotic exit network 1 homolog |
increases expression |
EXP |
masitinib results in increased expression of AMN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:17,044,301...17,100,444
Ensembl chr27:17,044,309...17,361,570
|
|
G |
ANKRD26 |
ankyrin repeat domain containing 26 |
increases expression |
EXP |
masitinib results in increased expression of ANKRD26 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:6,230,466...6,402,360
|
|
G |
ANP32E |
acidic nuclear phosphoprotein 32 family member E |
decreases expression |
EXP |
masitinib results in decreased expression of ANP32E mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:59,460,864...59,482,467
Ensembl chr17:59,462,766...59,477,936
|
|
G |
ANXA1 |
annexin A1 |
increases expression |
EXP |
masitinib results in increased expression of ANXA1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 1:84,744,159...84,763,011
Ensembl chr 1:84,744,163...84,763,011
|
|
G |
ANXA6 |
annexin A6 |
increases expression |
EXP |
masitinib results in increased expression of ANXA6 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:58,091,186...58,140,102
Ensembl chr 4:58,091,251...58,139,372
|
|
G |
ARMC12 |
armadillo repeat containing 12 |
increases expression |
EXP |
masitinib results in increased expression of ARMC12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:4,868,831...4,879,801
Ensembl chr12:4,869,774...4,879,793
|
|
G |
ASCC1 |
activating signal cointegrator 1 complex subunit 1 |
decreases expression |
EXP |
masitinib results in decreased expression of ASCC1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:22,779,644...22,876,434
Ensembl chr 4:22,779,781...22,874,215
|
|
G |
B4GALT7 |
beta-1,4-galactosyltransferase 7 |
increases expression |
EXP |
masitinib results in increased expression of B4GALT7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:3,497,860...3,507,513
Ensembl chr11:3,498,153...3,505,034
|
|
G |
BIRC5 |
baculoviral IAP repeat containing 5 |
decreases expression |
EXP |
masitinib results in decreased expression of BIRC5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:2,930,308...2,959,307
|
|
G |
BTBD3 |
BTB domain containing 3 |
decreases expression |
EXP |
masitinib results in decreased expression of BTBD3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:10,478,635...10,512,773
Ensembl chr24:10,479,900...10,512,185
|
|
G |
CA2 |
carbonic anhydrase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of CA2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr29:31,959,225...31,975,309
Ensembl chr29:31,935,172...31,980,579
|
|
G |
CAMK2G |
calcium/calmodulin dependent protein kinase II gamma |
increases expression |
EXP |
masitinib results in increased expression of CAMK2G mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:24,244,063...24,299,362
Ensembl chr 4:24,245,960...24,299,357
|
|
G |
CAPG |
capping actin protein, gelsolin like |
increases expression |
EXP |
masitinib results in increased expression of CAPG protein |
CTD |
PMID:22747577 |
|
NCBI chr17:39,619,429...39,640,944
Ensembl chr17:39,619,248...39,640,942
|
|
G |
CCT2 |
chaperonin containing TCP1 subunit 2 |
decreases expression |
EXP |
masitinib results in decreased expression of CCT2 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:11,560,287...11,586,559
Ensembl chr10:11,560,396...11,578,433
|
|
G |
CD5L |
CD5 molecule like |
increases expression |
EXP |
masitinib results in increased expression of CD5L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:40,516,190...40,526,528
Ensembl chr 7:40,516,190...40,526,528
|
|
G |
CDADC1 |
cytidine and dCMP deaminase domain containing 1 |
increases expression |
EXP |
masitinib results in increased expression of CDADC1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr22:2,443,459...2,489,147
Ensembl chr22:2,436,206...2,489,016
|
|
G |
CDKN1A |
cyclin dependent kinase inhibitor 1A |
increases expression |
EXP |
masitinib results in increased expression of CDKN1A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:5,746,898...5,755,103
Ensembl chr12:5,745,852...5,892,281
|
|
G |
CIAPIN1 |
cytokine induced apoptosis inhibitor 1 |
decreases expression |
EXP |
masitinib results in decreased expression of CIAPIN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:58,977,592...58,992,785
Ensembl chr 2:58,977,676...58,992,581
|
|
G |
CIRBP |
cold inducible RNA binding protein |
increases expression |
EXP |
masitinib results in increased expression of CIRBP mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:57,521,609...57,526,526
Ensembl chr20:57,519,119...57,526,435
|
|
G |
CLEC2B |
C-type lectin domain family 2 member B |
decreases expression |
EXP |
masitinib results in decreased expression of CLEC2B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:36,088,754...36,143,581
Ensembl chr27:36,120,134...36,143,040
|
|
G |
CMTM7 |
CKLF like MARVEL transmembrane domain containing 7 |
increases expression |
EXP |
masitinib results in increased expression of CMTM7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:12,317,636...12,382,836
Ensembl chr23:12,328,303...12,382,837
|
|
G |
CORO1A |
coronin 1A |
increases expression |
EXP |
masitinib results in increased expression of CORO1A protein |
CTD |
PMID:22747577 |
|
NCBI chr 6:18,161,850...18,167,915
Ensembl chr 6:18,160,601...18,167,818
|
|
G |
CPNE1 |
copine 1 |
increases expression |
EXP |
masitinib results in increased expression of CPNE1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,554,636...24,589,748
Ensembl chr24:24,554,636...24,589,731
|
|
G |
CPNE6 |
copine 6 |
increases expression |
EXP |
masitinib results in increased expression of DHRS4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:4,046,532...4,058,498
Ensembl chr 8:4,046,544...4,084,744
|
|
G |
CTSK |
cathepsin K |
increases expression |
EXP |
masitinib results in increased expression of CTSK mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:59,928,725...59,938,293
Ensembl chr17:59,929,287...59,938,507
|
|
G |
DLA-12 |
MHC class I DLA-12 |
increases expression |
EXP |
masitinib results in increased expression of DLA-12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:933,321...936,671
Ensembl chr12:932,613...987,561
|
|
G |
DLA-64 |
MHC class I DLA-64 |
increases expression |
EXP |
masitinib results in increased expression of DLA-64 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:983,573...986,969
|
|
G |
DLGAP1 |
DLG associated protein 1 |
decreases expression |
EXP |
masitinib results in decreased expression of DLGAP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:70,082,563...70,949,116
Ensembl chr 7:70,081,885...70,406,213
|
|
G |
DLGAP5 |
DLG associated protein 5 |
decreases expression |
EXP |
masitinib results in decreased expression of DLGAP5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:30,998,806...31,038,614
Ensembl chr 8:30,994,402...31,036,540
|
|
G |
DPCD |
deleted in primary ciliary dyskinesia homolog |
decreases expression |
EXP |
masitinib results in decreased expression of DPCD mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:14,201,302...14,219,121
Ensembl chr28:14,201,351...14,219,121
|
|
G |
DPYSL3 |
dihydropyrimidinase like 3 |
decreases expression |
EXP |
masitinib results in decreased expression of DPYSL3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:41,687,725...41,809,402
Ensembl chr 2:41,690,845...41,802,376
|
|
G |
EBPL |
EBP like |
increases expression |
EXP |
masitinib results in increased expression of EBPL mRNA |
CTD |
PMID:22747577 |
|
NCBI chr22:2,116,588...2,137,935
Ensembl chr22:2,116,131...2,182,633
|
|
G |
EDEM2 |
ER degradation enhancing alpha-mannosidase like protein 2 |
increases expression |
EXP |
masitinib results in increased expression of EDEM2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,137,228...24,165,995
Ensembl chr24:24,137,228...24,165,968
|
|
G |
EIF3A |
eukaryotic translation initiation factor 3 subunit A |
decreases expression |
EXP |
masitinib results in decreased expression of EIF3A protein |
CTD |
PMID:22747577 |
|
NCBI chr28:29,290,668...29,326,851
Ensembl chr28:29,291,422...29,326,701
|
|
G |
EIF4A1 |
eukaryotic translation initiation factor 4A1 |
decreases expression |
EXP |
masitinib results in decreased expression of EIF4A1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 5:32,495,606...32,500,805
Ensembl chr 5:32,484,572...32,500,805
|
|
G |
EIF5A2 |
eukaryotic translation initiation factor 5A2 |
decreases expression |
EXP |
masitinib results in decreased expression of EIF5A2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:35,309,812...35,322,382
Ensembl chr34:35,314,172...35,322,392
|
|
G |
ELSPBP1 |
epididymal sperm binding protein 1 |
increases expression |
EXP |
masitinib results in increased expression of ELSPBP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:108,159,609...108,187,224
Ensembl chr 1:108,159,611...108,188,076
|
|
G |
ETFDH |
electron transfer flavoprotein dehydrogenase |
decreases expression |
EXP |
masitinib results in decreased expression of ETFDH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr15:55,752,170...55,781,118
Ensembl chr15:55,752,200...55,792,105
|
|
G |
GGT1 |
gamma-glutamyltransferase 1 |
increases expression |
EXP |
masitinib results in increased expression of GGT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:28,301,455...28,315,029
|
|
G |
GKN1 |
gastrokine 1 |
increases expression |
EXP |
masitinib results in increased expression of GKN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:67,788,329...67,793,445
Ensembl chr10:67,788,110...67,793,589
|
|
G |
GMFB |
glia maturation factor beta |
decreases expression |
EXP |
masitinib results in decreased expression of GMFB mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:30,394,020...30,408,408
Ensembl chr 8:30,359,499...30,408,357
|
|
G |
GSTA4 |
glutathione S-transferase alpha 4 |
increases expression |
EXP |
masitinib results in increased expression of GSTA4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:20,426,724...20,443,200
Ensembl chr12:20,426,726...20,443,200
|
|
G |
GXYLT1 |
glucoside xylosyltransferase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of GXYLT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:11,754,609...11,810,245
Ensembl chr27:11,765,072...11,807,787
|
|
G |
HEBP2 |
heme binding protein 2 |
decreases expression |
EXP |
masitinib results in decreased expression of HEBP2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:30,716,395...30,724,814
Ensembl chr 1:30,716,606...30,724,613
|
|
G |
HERPUD1 |
homocysteine inducible ER protein with ubiquitin like domain 1 |
increases expression |
EXP |
masitinib results in increased expression of HERPUD1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:59,388,492...59,400,028
Ensembl chr 2:59,388,494...59,400,003
|
|
G |
HSP90B1 |
heat shock protein 90 beta family member 1 |
increases expression |
EXP |
masitinib results in increased expression of HSP90B1 protein |
CTD |
PMID:22747577 |
|
NCBI chr15:42,456,793...42,474,122
Ensembl chr15:42,456,764...42,579,311
|
|
G |
HTR2B |
5-hydroxytryptamine receptor 2B |
increases expression |
EXP |
masitinib results in increased expression of HTR2B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr25:43,042,306...43,056,361
Ensembl chr25:43,042,173...43,056,612
|
|
G |
HYAL3 |
hyaluronidase 3 |
increases expression |
EXP |
masitinib results in increased expression of HYAL3 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr20:39,041,940...39,047,388
Ensembl chr20:39,042,070...39,047,365
|
|
G |
IGFBP7 |
insulin like growth factor binding protein 7 |
increases expression |
EXP |
masitinib results in increased expression of IGFBP7 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:49,138,406...49,207,235
Ensembl chr13:49,138,402...49,207,394
|
|
G |
IL13 |
interleukin 13 |
increases expression |
EXP |
masitinib results in increased expression of IL13 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:20,957,870...20,961,391
Ensembl chr11:20,958,464...20,961,388
|
|
G |
IMMP2L |
inner mitochondrial membrane peptidase subunit 2 |
increases expression |
EXP |
masitinib results in increased expression of IMMP2L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr14:50,487,679...51,336,906
|
|
G |
IRX6 |
iroquois homeobox 6 |
increases expression |
EXP |
masitinib results in increased expression of IRX6 protein |
CTD |
PMID:22747577 |
|
NCBI chr 2:60,630,688...60,636,285
Ensembl chr 2:60,630,447...60,636,416
|
|
G |
ITGA6 |
integrin subunit alpha 6 |
decreases expression |
EXP |
masitinib results in decreased expression of ITGA6 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr36:16,777,363...16,858,725
Ensembl chr36:16,776,863...16,855,449
|
|
G |
JAML |
junction adhesion molecule like |
decreases expression |
EXP |
masitinib results in decreased expression of JAML mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:15,485,378...15,513,457
Ensembl chr 5:15,476,582...15,513,075
|
|
G |
JUN |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
masitinib results in increased expression of JUN mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:50,966,698...50,968,939
|
|
G |
KCTD19 |
potassium channel tetramerization domain containing 19 |
increases expression |
EXP |
masitinib results in increased expression of KCTD19 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:82,060,946...82,093,248
Ensembl chr 5:82,061,449...82,093,246
|
|
G |
KLHL5 |
kelch like family member 5 |
increases expression |
EXP |
masitinib results in increased expression of KLHL5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:73,258,925...73,347,262
Ensembl chr 3:73,262,895...73,344,879
|
|
G |
LBX2 |
ladybird homeobox 2 |
increases expression |
EXP |
masitinib results in increased expression of LBX2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:48,641,630...48,643,411
Ensembl chr17:48,641,674...48,643,239
|
|
G |
LIN7C |
lin-7 homolog C, crumbs cell polarity complex component |
decreases expression |
EXP |
masitinib results in decreased expression of LIN7C mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:48,061,446...48,071,458
Ensembl chr21:48,064,929...48,071,429
|
|
G |
LOC474850 |
heat shock 70 kDa protein 1-like |
increases expression |
EXP |
masitinib results in increased expression of HSPA1L mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:1,281,164...1,285,010
Ensembl chr12:1,281,472...1,285,440
|
|
G |
LOC475707 |
GPN-loop GTPase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of GPN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:21,654,516...21,678,435
Ensembl chr17:21,545,673...21,673,157
|
|
G |
LOC478000 |
phytanoyl-CoA hydroxylase-like |
increases expression |
EXP |
masitinib results in increased expression of PHYH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:23,185,901...23,206,719
Ensembl chr 2:23,185,782...23,253,497
|
|
G |
LOC485255 |
hemoglobin subunit epsilon-2 |
increases expression |
EXP |
masitinib results in increased expression of HBG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:28,193,163...28,194,746
|
|
G |
LONRF1 |
LON peptidase N-terminal domain and ring finger 1 |
increases expression |
EXP |
masitinib results in increased expression of LONRF1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:36,220,324...36,256,896
Ensembl chr16:36,221,156...36,256,897
|
|
G |
LRP1 |
LDL receptor related protein 1 |
increases expression |
EXP |
masitinib results in increased expression of LRP1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:1,260,256...1,341,705
Ensembl chr10:1,260,719...1,352,271
|
|
G |
LRP8 |
LDL receptor related protein 8 |
decreases expression |
EXP |
masitinib results in decreased expression of LRP8 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:55,604,878...55,684,666
Ensembl chr 5:55,604,878...55,699,736
|
|
G |
LYRM1 |
LYR motif containing 1 |
increases expression |
EXP |
masitinib results in increased expression of LYRM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:24,428,461...24,460,291
Ensembl chr 6:24,441,307...24,460,331
|
|
G |
MAGEF1 |
MAGE family member F1 |
decreases expression |
EXP |
masitinib results in decreased expression of MAGEF1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:17,543,381...17,545,089
Ensembl chr34:17,543,906...17,544,868
|
|
G |
MOB1B |
MOB kinase activator 1B |
decreases expression |
EXP |
masitinib results in decreased expression of MOB1B mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:60,145,168...60,197,916
Ensembl chr13:60,145,366...60,195,463
|
|
G |
MPDZ |
multiple PDZ domain crumbs cell polarity complex component |
increases expression |
EXP |
masitinib results in increased expression of MPDZ mRNA |
CTD |
PMID:22747577 |
|
NCBI chr11:33,691,434...33,826,500
Ensembl chr11:33,692,296...33,826,437
|
|
G |
MYOZ1 |
myozenin 1 |
increases expression |
EXP |
masitinib results in increased expression of MYOZ1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:24,158,532...24,165,416
Ensembl chr 4:24,158,720...24,165,392
|
|
G |
NAPG |
NSF attachment protein gamma |
decreases expression |
EXP |
masitinib results in decreased expression of NAPG mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:76,403,561...76,424,994
Ensembl chr 7:76,403,595...76,423,170
|
|
G |
NDUFS1 |
NADH:ubiquinone oxidoreductase core subunit S1 |
decreases expression |
EXP |
masitinib results in decreased expression of NDUFS1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:14,680,908...14,713,838
Ensembl chr37:14,683,083...14,713,754
|
|
G |
NFKBIA |
NFKB inhibitor alpha |
increases expression |
EXP |
masitinib results in increased expression of NFKBIA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:14,100,203...14,103,453
Ensembl chr 8:14,100,671...14,103,433
|
|
G |
NRAS |
NRAS proto-oncogene, GTPase |
decreases expression |
EXP |
masitinib results in decreased expression of NRAS mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,411,733...52,418,788
Ensembl chr17:52,411,733...52,418,788
|
|
G |
NSG1 |
neuronal vesicle trafficking associated 1 |
decreases expression |
EXP |
masitinib results in decreased expression of NSG1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:69,805,646...69,831,200
Ensembl chr 3:69,805,592...69,831,194
|
|
G |
NTRK1 |
neurotrophic receptor tyrosine kinase 1 |
increases expression |
EXP |
masitinib results in increased expression of NTRK1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:41,140,931...41,159,326
Ensembl chr 7:41,140,879...41,159,288
|
|
G |
OCA2 |
OCA2 melanosomal transmembrane protein |
decreases expression |
EXP |
masitinib results in decreased expression of OCA2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:32,361,825...32,713,631
Ensembl chr 3:32,361,517...32,713,572
|
|
G |
OGT |
O-linked N-acetylglucosamine (GlcNAc) transferase |
increases expression |
EXP |
masitinib results in increased expression of OGT mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:55,821,227...55,857,597
Ensembl chr X:55,821,234...55,855,502
|
|
G |
OXCT1 |
3-oxoacid CoA-transferase 1 |
increases expression |
EXP |
masitinib results in increased expression of OXCT1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:67,709,846...67,841,737
Ensembl chr 4:67,527,531...67,841,518
|
|
G |
PARP14 |
poly(ADP-ribose) polymerase family member 14 |
increases expression |
EXP |
masitinib results in increased expression of PARP14 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr33:25,763,282...25,798,284
Ensembl chr33:25,763,255...25,798,198
|
|
G |
PCM1 |
pericentriolar material 1 |
increases expression |
EXP |
masitinib results in increased expression of PCM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:41,212,733...41,291,654
Ensembl chr16:41,214,417...41,291,376
|
|
G |
PCOLCE2 |
procollagen C-endopeptidase enhancer 2 |
decreases expression |
EXP |
masitinib results in decreased expression of PCOLCE2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:38,424,408...38,486,800
Ensembl chr23:38,426,216...38,487,252
|
|
G |
PDE6H |
phosphodiesterase 6H |
increases expression |
EXP |
masitinib results in increased expression of PDE6H mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:31,640,731...31,664,494
Ensembl chr27:31,640,737...31,664,401
|
|
G |
PDHA1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
decreases expression |
EXP |
masitinib results in decreased expression of PDHA1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:15,338,364...15,354,011
Ensembl chr X:15,338,202...15,387,458
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases expression |
EXP |
masitinib results in increased expression of PDIA3 protein |
CTD |
PMID:22747577 |
|
NCBI chr30:10,487,926...10,513,437
Ensembl chr30:10,487,921...10,513,397
|
|
G |
PEBP4 |
phosphatidylethanolamine binding protein 4 |
increases expression |
EXP |
masitinib results in increased expression of PEBP4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr25:34,329,160...34,574,086
Ensembl chr25:34,317,421...34,574,066
|
|
G |
PECAM1 |
platelet and endothelial cell adhesion molecule 1 |
increases expression |
EXP |
masitinib results in increased expression of PECAM1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:12,166,124...12,219,553
Ensembl chr 9:12,166,775...12,219,778
|
|
G |
PHF10 |
PHD finger protein 10 |
increases expression |
EXP |
masitinib results in increased expression of PHF10 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:71,955,354...71,998,283
Ensembl chr12:71,787,082...71,998,243
|
|
G |
POMT1 |
protein O-mannosyltransferase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of POMT1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 9:52,615,349...52,631,538
Ensembl chr 9:52,615,655...52,630,836
|
|
G |
POR |
cytochrome p450 oxidoreductase |
increases expression |
EXP |
masitinib results in increased expression of POR mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:7,247,780...7,316,282
Ensembl chr 6:7,263,574...7,316,297
|
|
G |
PPA1 |
inorganic pyrophosphatase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of PPA1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 4:21,145,547...21,189,985
Ensembl chr 4:21,145,547...21,182,748
|
|
G |
PRPS2 |
phosphoribosyl pyrophosphate synthetase 2 |
decreases expression |
EXP |
masitinib results in decreased expression of PRPS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr X:9,281,686...9,326,551
Ensembl chr X:9,281,730...9,418,289
|
|
G |
PSMB9 |
proteasome 20S subunit beta 9 |
increases expression |
EXP |
masitinib results in increased expression of PSMB9 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:2,432,287...2,438,920
Ensembl chr12:2,432,505...2,438,069
|
|
G |
PSMD6 |
proteasome 26S subunit, non-ATPase 6 |
decreases expression |
EXP |
masitinib results in decreased expression of PSMD6 protein |
CTD |
PMID:22747577 |
|
NCBI chr20:27,206,801...27,220,059
|
|
G |
PSMD9 |
proteasome 26S subunit, non-ATPase 9 |
decreases expression |
EXP |
masitinib results in decreased expression of PSMD9 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:7,376,154...7,400,655
Ensembl chr26:7,377,413...7,400,573
|
|
G |
PTH |
parathyroid hormone |
increases expression |
EXP |
masitinib results in increased expression of PTH mRNA |
CTD |
PMID:22747577 |
|
NCBI chr21:36,417,062...36,419,967
Ensembl chr21:36,417,058...36,419,967
|
|
G |
PXYLP1 |
2-phosphoxylose phosphatase 1 |
decreases expression |
EXP |
masitinib results in decreased expression of ACPL2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:37,145,065...37,197,808
Ensembl chr23:37,145,086...37,196,427
|
|
G |
R3HDM2 |
R3H domain containing 2 |
increases expression |
EXP |
masitinib results in increased expression of R3HDM2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:1,377,664...1,504,008
Ensembl chr10:1,370,350...1,504,017
|
|
G |
RAB44 |
RAB44, member RAS oncogene family |
increases expression |
EXP |
masitinib results in increased expression of RAB44 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr12:5,769,056...5,804,963
Ensembl chr12:5,770,882...5,804,949
|
|
G |
RASGRP2 |
RAS guanyl releasing protein 2 |
increases expression |
EXP |
masitinib results in increased expression of RASGRP2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr18:52,412,331...52,426,910
Ensembl chr18:52,412,367...52,426,916
|
|
G |
RCAN1 |
regulator of calcineurin 1 |
increases expression |
EXP |
masitinib results in increased expression of RCAN1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr31:29,908,046...30,002,412
Ensembl chr31:29,909,388...30,002,418
|
|
G |
RGS13 |
regulator of G protein signaling 13 |
decreases expression |
EXP |
masitinib results in decreased expression of RGS13 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr38:6,291,146...6,316,662
Ensembl chr38:6,291,182...6,315,198
|
|
G |
SAR1A |
secretion associated Ras related GTPase 1A |
decreases expression |
EXP |
masitinib results in decreased expression of SAR1A mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:21,120,788...21,136,409
Ensembl chr 4:21,123,028...21,136,973
|
|
G |
SCD |
stearoyl-CoA desaturase |
decreases expression |
EXP |
masitinib results in decreased expression of SCD mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:13,112,741...13,129,129
Ensembl chr28:13,113,006...13,125,801
|
|
G |
SELENBP1 |
selenium binding protein 1 |
increases expression |
EXP |
masitinib results in increased expression of SELENBP1 protein |
CTD |
PMID:22747577 |
|
NCBI chr17:60,410,727...60,418,770
Ensembl chr17:60,410,734...60,418,704
|
|
G |
SERPINE2 |
serpin family E member 2 |
increases expression |
EXP |
masitinib results in increased expression of SERPINE2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:29,699,551...29,750,151
Ensembl chr37:29,700,024...29,724,228
|
|
G |
SFT2D2 |
SFT2 domain containing 2 |
decreases expression |
EXP |
masitinib results in decreased expression of SFT2D2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 7:30,258,748...30,281,371
|
|
G |
SLA |
Src like adaptor |
increases expression |
EXP |
masitinib results in increased expression of SLA mRNA |
CTD |
PMID:22747577 |
|
NCBI chr13:29,503,304...29,590,679
Ensembl chr13:29,504,867...29,569,773
|
|
G |
SLC25A12 |
solute carrier family 25 member 12 |
decreases expression |
EXP |
masitinib results in decreased expression of SLC25A12 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr36:16,185,011...16,391,080
Ensembl chr36:16,185,649...16,483,016
|
|
G |
SMC5 |
structural maintenance of chromosomes 5 |
decreases expression |
EXP |
masitinib results in decreased expression of SMC5 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 1:87,192,988...87,285,678
Ensembl chr 1:87,194,867...87,285,606
|
|
G |
SRR |
serine racemase |
increases expression |
EXP |
masitinib results in increased expression of SRR mRNA |
CTD |
PMID:22747577 |
|
|
|
G |
STING1 |
stimulator of interferon response cGAMP interactor 1 |
increases expression |
EXP |
masitinib results in increased expression of TMEM173 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:34,783,947...34,792,204
Ensembl chr 2:34,784,232...34,789,072
|
|
G |
STOX1 |
storkhead box 1 |
increases expression |
EXP |
masitinib results in increased expression of STOX1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:20,013,893...20,065,480
Ensembl chr 4:20,014,007...20,060,394
|
|
G |
STX16 |
syntaxin 16 |
increases expression |
EXP |
masitinib results in increased expression of STX16 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:43,425,719...43,451,828
Ensembl chr24:43,426,470...43,449,077
|
|
G |
STYXL1 |
serine/threonine/tyrosine interacting like 1 |
increases expression |
EXP |
masitinib results in increased expression of STYXL1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 6:7,323,911...7,389,878
Ensembl chr 6:7,316,477...7,389,842
|
|
G |
TARDBP |
TAR DNA binding protein |
decreases expression |
EXP |
masitinib results in decreased expression of TARDBP protein |
CTD |
PMID:22747577 |
|
NCBI chr 2:84,987,752...84,998,136
Ensembl chr 2:84,989,952...84,998,593
|
|
G |
TBC1D14 |
TBC1 domain family member 14 |
decreases expression |
EXP |
masitinib results in decreased expression of TBC1D14 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 3:58,992,743...59,097,581
Ensembl chr 3:58,926,237...59,097,621
|
|
G |
TCN2 |
transcobalamin 2 |
increases expression |
EXP |
masitinib results in increased expression of TCN2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr26:23,693,664...23,710,342
Ensembl chr26:23,693,773...23,709,832
|
|
G |
TCP1 |
t-complex 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TCP1 protein |
CTD |
PMID:22747577 |
|
NCBI chr 1:49,029,260...49,038,023
Ensembl chr 1:49,029,282...49,038,020
|
|
G |
TEAD4 |
TEA domain transcription factor 4 |
increases expression |
EXP |
masitinib results in increased expression of TEAD4 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr27:41,744,100...41,783,223
Ensembl chr27:41,748,871...41,803,556
|
|
G |
THEMIS2 |
thymocyte selection associated family member 2 |
decreases expression |
EXP |
masitinib results in decreased expression of THEMIS2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:72,465,719...72,501,962
Ensembl chr 2:72,464,026...72,502,928
|
|
G |
TM2D2 |
TM2 domain containing 2 |
increases expression |
EXP |
masitinib results in increased expression of TM2D2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr16:26,551,563...26,557,554
Ensembl chr16:26,551,628...26,556,285
|
|
G |
TMEM108 |
transmembrane protein 108 |
increases expression |
EXP |
masitinib results in increased expression of TMEM108 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr23:29,992,038...30,331,791
Ensembl chr23:29,992,021...30,396,840
|
|
G |
TMEM260 |
transmembrane protein 260 |
increases expression |
EXP |
masitinib results in increased expression of TMEM260 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:32,238,992...32,309,320
Ensembl chr 8:32,238,988...32,306,317
|
|
G |
TNFSF10 |
TNF superfamily member 10 |
increases expression |
EXP |
masitinib results in increased expression of TNFSF10 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr34:36,719,249...36,734,989
Ensembl chr34:36,670,849...36,735,060
|
|
G |
TNPO1 |
transportin 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TNPO1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 2:55,795,737...55,859,366
Ensembl chr 2:55,799,907...55,851,213
|
|
G |
TNS1 |
tensin 1 |
decreases expression |
EXP |
masitinib results in decreased expression of TNS1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr37:24,578,855...24,776,153
Ensembl chr37:24,581,806...24,808,049
|
|
G |
TOX |
thymocyte selection associated high mobility group box |
increases expression |
EXP |
masitinib results in increased expression of TOX mRNA |
CTD |
PMID:22747577 |
|
NCBI chr29:9,542,471...9,841,759
Ensembl chr29:9,544,561...9,842,034
|
|
G |
TSHB |
thyroid stimulating hormone subunit beta |
increases expression |
EXP |
masitinib results in increased expression of TSHB mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,659,137...52,685,388
Ensembl chr17:52,681,357...52,685,390
|
|
G |
TSPAN2 |
tetraspanin 2 |
increases expression |
EXP |
masitinib results in increased expression of TSPAN2 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr17:52,692,744...52,749,048
Ensembl chr17:52,694,603...52,744,276
|
|
G |
TTC38 |
tetratricopeptide repeat domain 38 |
increases expression |
EXP |
masitinib results in increased expression of TTC38 protein |
CTD |
PMID:22747577 |
|
NCBI chr10:19,887,285...19,910,347
Ensembl chr10:19,773,373...19,910,683
|
|
G |
TTLL1 |
TTL family tubulin polyglutamylase complex subunit L1 |
decreases expression |
EXP |
masitinib results in decreased expression of TTLL1 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr10:22,456,150...22,492,375
Ensembl chr10:22,456,146...22,488,505
|
|
G |
UCHL3 |
ubiquitin C-terminal hydrolase L3 |
increases expression |
EXP |
masitinib results in increased expression of UCHL3 protein |
CTD |
PMID:22747577 |
|
NCBI chr22:29,348,962...29,397,944
Ensembl chr22:29,348,706...29,407,965
|
|
G |
UQCC1 |
ubiquinol-cytochrome c reductase complex assembly factor 1 |
decreases expression |
EXP |
masitinib results in decreased expression of UQCC mRNA |
CTD |
PMID:22747577 |
|
NCBI chr24:24,285,147...24,381,819
Ensembl chr24:24,286,320...24,381,699
|
|
G |
UROD |
uroporphyrinogen decarboxylase |
increases expression |
EXP |
masitinib results in increased expression of UROD protein |
CTD |
PMID:22747577 |
|
NCBI chr15:15,313,808...15,317,130
Ensembl chr15:15,312,674...15,320,010
|
|
G |
UROS |
uroporphyrinogen III synthase |
increases expression |
EXP |
masitinib results in increased expression of UROS mRNA |
CTD |
PMID:22747577 |
|
NCBI chr28:34,952,074...34,983,532
Ensembl chr28:34,948,003...34,983,532
|
|
G |
VCPKMT |
valosin containing protein lysine methyltransferase |
decreases expression |
EXP |
masitinib results in decreased expression of VCPKMT mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 8:26,611,333...26,636,700
Ensembl chr 8:26,625,677...26,636,316
|
|
G |
WAPL |
WAPL cohesin release factor |
decreases expression |
EXP |
masitinib results in decreased expression of WAPAL mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 4:34,219,644...34,297,456
Ensembl chr 4:34,219,645...34,302,839
|
|
G |
YWHAZ |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta |
increases expression |
EXP |
masitinib results in increased expression of YWHAZ protein |
CTD |
PMID:22747577 |
|
NCBI chr13:2,729,404...2,764,422
|
|
G |
ZNF23 |
zinc finger protein 23 |
increases expression |
EXP |
masitinib results in increased expression of ZNF23 mRNA |
CTD |
PMID:22747577 |
|
NCBI chr 5:77,246,374...77,260,761
Ensembl chr 5:77,246,667...77,260,350
|
|
|
G |
GNAQ |
G protein subunit alpha q |
multiple interactions |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased activity of and affects the localization of GNAQ protein]; mastoparan results in increased activity of and affects the localization of GNAQ protein |
CTD |
PMID:21671308 |
|
NCBI chr 1:80,733,530...80,928,065
Ensembl chr 1:80,715,366...80,928,065
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions increases secretion |
EXP |
G(M1) Ganglioside inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; ganglioside, GD1a inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Indomethacin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; methyl-beta-cyclodextrin promotes the reaction [mastoparan results in increased secretion of HEXB protein]; Pertussis Toxin inhibits the reaction [mastoparan results in increased secretion of HEXB protein]; Quinacrine promotes the reaction [mastoparan results in increased secretion of HEXB protein]; YM-254890 inhibits the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions increases secretion |
EXP |
G(M1) Ganglioside inhibits the reaction [Melitten results in increased secretion of HEXB protein]; sialogangliosides inhibits the reaction [Melitten results in increased secretion of HEXB protein]; trisialoganglioside GT1 inhibits the reaction [Melitten results in increased secretion of HEXB protein] |
CTD |
PMID:21334356 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases hydroxylation |
EXP |
CYP2B6 protein results in increased hydroxylation of Mephenytoin |
CTD |
PMID:12637241 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of ATP2A2 protein |
CTD |
PMID:18820026 |
|
NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
|
|
G |
CYP2D15 |
cytochrome P450 family 2 subfamily D member 15 |
affects metabolic processing |
EXP |
CYP2D15 affects the metabolism of Metoprolol |
CTD |
PMID:7786018 |
|
NCBI chr10:23,255,259...23,259,380
Ensembl chr10:23,255,249...23,259,298
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of EGR1 protein |
CTD |
PMID:18820026 |
|
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
|
|
G |
GATA4 |
GATA binding protein 4 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of GATA4 protein |
CTD |
PMID:18820026 |
|
NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
|
|
G |
NAB1 |
NGFI-A binding protein 1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of NAB1 protein |
CTD |
PMID:18820026 |
|
NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
multiple interactions |
EXP |
[Ranolazine co-treated with Metoprolol] affects the expression of SLC8A1 protein |
CTD |
PMID:18820026 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases response to substance |
EXP |
ABCB1 mutant form results in increased susceptibility to Mexiletine |
CTD |
PMID:16594604 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
affects metabolic processing |
EXP |
CYP3A4 protein affects the metabolism of Midazolam; CYP3A5 protein affects the metabolism of Midazolam |
CTD |
PMID:15801540 |
|
NCBI chr 6:9,836,685...9,869,520
Ensembl chr 6:9,777,659...9,869,352
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] |
CTD |
PMID:20510202 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
MYLK |
myosin light chain kinase |
multiple interactions |
EXP |
[ML 7 results in decreased activity of MYLK protein] affects the reaction [ABCB1 protein affects the transport of Digoxin] |
CTD |
PMID:20510202 |
|
NCBI chr33:26,663,991...26,867,370
Ensembl chr33:26,664,800...26,843,181
|
|
|
G |
AKAP12 |
A-kinase anchoring protein 12 |
increases expression |
EXP |
mocetinostat results in increased expression of AKAP12 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:41,614,893...41,712,350
Ensembl chr 1:41,614,714...41,709,798
|
|
G |
ANK1 |
ankyrin 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of ANK1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr16:23,858,299...23,966,181
Ensembl chr16:23,766,193...23,964,226
|
|
G |
ANK3 |
ankyrin 3 |
increases expression |
EXP |
mocetinostat results in increased expression of ANK3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:12,166,275...12,827,175
Ensembl chr 4:12,167,550...12,827,037
|
|
G |
AP2M1 |
adaptor related protein complex 2 subunit mu 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of AP2M1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr34:17,071,199...17,080,445
Ensembl chr34:17,071,235...17,080,445
|
|
G |
AP2S1 |
adaptor related protein complex 2 subunit sigma 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of AP2S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:109,094,098...109,105,233
Ensembl chr 1:109,082,221...109,105,230
|
|
G |
AP3S1 |
adaptor related protein complex 3 subunit sigma 1 |
increases expression |
EXP |
mocetinostat results in increased expression of AP3S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr11:5,543,140...5,611,322
Ensembl chr11:5,543,222...5,610,930
|
|
G |
ARF4 |
ADP ribosylation factor 4 |
increases expression |
EXP |
mocetinostat results in increased expression of ARF4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:32,849,725...32,871,127
Ensembl chr20:32,849,757...32,870,721
|
|
G |
ATG4D |
autophagy related 4D cysteine peptidase |
decreases expression |
EXP |
mocetinostat results in decreased expression of ATG4D mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:50,618,458...50,623,703
Ensembl chr20:50,618,459...50,624,179
|
|
G |
ATG7 |
autophagy related 7 |
decreases expression |
EXP |
mocetinostat results in decreased expression of ATG7 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:6,916,354...7,154,849
Ensembl chr20:6,916,515...7,154,800
|
|
G |
ATP1A1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression |
EXP |
mocetinostat results in increased expression of ATP1A1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:53,828,482...53,847,043
Ensembl chr17:53,813,976...53,847,167
|
|
G |
BCAP29 |
B cell receptor associated protein 29 |
increases expression |
EXP |
mocetinostat results in increased expression of BCAP29 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr18:12,969,594...13,021,948
Ensembl chr18:12,970,411...13,022,022
|
|
G |
BLOC1S1 |
biogenesis of lysosomal organelles complex 1 subunit 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of BLOC1S1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:116,993...120,244
|
|
G |
BNIP1 |
BCL2 interacting protein 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of BNIP1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:39,255,685...39,303,485
Ensembl chr 4:39,289,776...39,303,430
|
|
G |
CACNB3 |
calcium voltage-gated channel auxiliary subunit beta 3 |
increases expression |
EXP |
mocetinostat results in increased expression of CACNB3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr27:5,705,587...5,714,620
Ensembl chr27:5,706,064...5,717,647
|
|
G |
CAMK1D |
calcium/calmodulin dependent protein kinase ID |
increases expression |
EXP |
mocetinostat results in increased expression of CAMK1D mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 2:23,680,395...24,113,922
Ensembl chr 2:23,685,672...24,114,084
|
|
G |
CASK |
calcium/calmodulin dependent serine protein kinase |
increases expression |
EXP |
mocetinostat results in increased expression of CASK mRNA |
CTD |
PMID:27255383 |
|
NCBI chr X:35,939,117...36,296,438
Ensembl chr X:35,940,647...36,297,014
|
|
G |
CAV1 |
caveolin 1 |
increases expression |
EXP |
mocetinostat results in increased expression of CAV1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr14:55,458,934...55,494,563
Ensembl chr14:55,461,048...55,492,935
|
|
G |
CBY1 |
chibby 1, beta catenin antagonist |
decreases expression |
EXP |
mocetinostat results in decreased expression of CBY1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:26,125,064...26,134,693
Ensembl chr10:26,125,189...26,128,285
|
|
G |
CHMP4B |
charged multivesicular body protein 4B |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP4B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr24:22,995,677...23,050,084
Ensembl chr24:22,995,672...23,049,287
|
|
G |
CHMP5 |
charged multivesicular body protein 5 |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP5 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr11:50,363,488...50,376,081
|
|
G |
CHMP6 |
charged multivesicular body protein 6 |
decreases expression |
EXP |
mocetinostat results in decreased expression of CHMP6 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 9:997,951...1,001,659
Ensembl chr 9:998,653...1,002,538
|
|
G |
CLTCL1 |
clathrin heavy chain like 1 |
increases expression |
EXP |
mocetinostat results in increased expression of CLTCL1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:29,907,235...30,002,136
Ensembl chr26:29,906,278...30,002,128
|
|
G |
COPB1 |
COPI coat complex subunit beta 1 |
increases expression |
EXP |
mocetinostat results in increased expression of COPB1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr21:37,186,380...37,224,549
Ensembl chr21:37,186,424...37,224,519
|
|
G |
COPB2 |
COPI coat complex subunit beta 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of COPB2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr23:35,536,520...35,604,708
Ensembl chr23:35,536,615...35,566,569
|
|
G |
COPG1 |
COPI coat complex subunit gamma 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of COPG1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:2,832,150...2,860,356
Ensembl chr20:2,832,198...2,860,320
|
|
G |
DERL2 |
derlin 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of DERL2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 5:31,319,660...31,330,846
Ensembl chr 5:31,319,717...31,330,841
|
|
G |
DNM1L |
dynamin 1 like |
decreases expression |
EXP |
mocetinostat results in decreased expression of DNM1L mRNA |
CTD |
PMID:27255383 |
|
NCBI chr27:16,161,855...16,211,983
Ensembl chr27:16,163,357...16,211,957
|
|
G |
GPAA1 |
glycosylphosphatidylinositol anchor attachment 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of GPAA1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr13:37,577,162...37,580,346
Ensembl chr13:37,576,354...37,580,345
|
|
G |
HPS4 |
HPS4 biogenesis of lysosomal organelles complex 3 subunit 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of HPS4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:20,131,658...20,157,532
Ensembl chr26:19,933,281...20,157,058
|
|
G |
HRC |
histidine rich calcium binding protein |
decreases expression |
EXP |
mocetinostat results in decreased expression of HRC mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:107,304,718...107,308,741
Ensembl chr 1:107,304,924...107,308,740
|
|
G |
KCNK1 |
potassium two pore domain channel subfamily K member 1 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNK1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:6,117,406...6,139,390
Ensembl chr 4:6,118,373...6,122,093
|
|
G |
KCNMB4 |
potassium calcium-activated channel subfamily M regulatory beta subunit 4 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNMB4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:12,211,372...12,251,739
|
|
G |
KCNS3 |
potassium voltage-gated channel modifier subfamily S member 3 |
increases expression |
EXP |
mocetinostat results in increased expression of KCNS3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:13,297,242...13,338,319
Ensembl chr17:13,336,374...13,337,849
|
|
G |
KIF5A |
kinesin family member 5A |
increases expression |
EXP |
mocetinostat results in increased expression of KIF5A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:1,637,007...1,666,790
Ensembl chr10:1,636,932...1,664,767
|
|
G |
KIF5B |
kinesin family member 5B |
decreases expression |
EXP |
mocetinostat results in decreased expression of KIF5B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 2:14,835,906...14,880,896
Ensembl chr 2:14,835,901...14,878,251
|
|
G |
KIF5C |
kinesin family member 5C |
increases expression |
EXP |
mocetinostat results in increased expression of KIF5C mRNA |
CTD |
PMID:27255383 |
|
NCBI chr19:50,535,622...50,684,485
Ensembl chr19:50,535,456...50,668,738
|
|
G |
LAMTOR1 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of LAMTOR1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr21:25,981,170...25,986,942
Ensembl chr21:25,981,254...25,996,432
|
|
G |
LAMTOR2 |
late endosomal/lysosomal adaptor, MAPK and MTOR activator 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of LAMTOR2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 7:41,760,632...41,764,926
Ensembl chr 7:41,760,638...41,763,299
|
|
G |
LOC478702 |
tubulin beta-2B chain |
increases expression |
EXP |
mocetinostat results in increased expression of TUBB2B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr35:3,494,982...3,498,274
Ensembl chr35:3,495,277...3,498,248
|
|
G |
MAL2 |
mal, T cell differentiation protein 2 |
increases expression |
EXP |
mocetinostat results in increased expression of MAL2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr13:18,404,979...18,422,076
Ensembl chr13:18,406,633...18,420,469
|
|
G |
MICAL1 |
microtubule associated monooxygenase, calponin and LIM domain containing 1 |
increases expression |
EXP |
mocetinostat results in increased expression of MICAL1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr12:66,350,459...66,358,391
Ensembl chr12:66,350,427...66,360,615
|
|
G |
MYPN |
myopalladin |
decreases expression |
EXP |
mocetinostat results in decreased expression of MYPN mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:19,364,146...19,468,827
Ensembl chr 4:19,381,416...19,465,995
|
|
G |
PEX19 |
peroxisomal biogenesis factor 19 |
decreases expression |
EXP |
mocetinostat results in decreased expression of PEX19 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr38:21,939,054...21,945,281
Ensembl chr38:21,939,018...21,944,602
|
|
G |
POLE2 |
DNA polymerase epsilon 2, accessory subunit |
increases expression |
EXP |
mocetinostat results in increased expression of DNAAF2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 8:26,264,220...26,295,089
Ensembl chr 8:26,251,160...26,295,317
|
|
G |
PPP3CA |
protein phosphatase 3 catalytic subunit alpha |
increases expression |
EXP |
mocetinostat results in increased expression of PPP3CA mRNA |
CTD |
PMID:27255383 |
|
NCBI chr32:22,688,141...22,996,693
Ensembl chr32:22,688,143...22,996,688
|
|
G |
RAB27A |
RAB27A, member RAS oncogene family |
increases expression |
EXP |
mocetinostat results in increased expression of RAB27A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr30:20,633,576...20,706,240
Ensembl chr30:20,635,400...20,690,521
|
|
G |
RAB31 |
RAB31, member RAS oncogene family |
increases expression |
EXP |
mocetinostat results in increased expression of RAB31 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 7:75,678,896...75,807,716
Ensembl chr 7:75,678,908...75,817,426
|
|
G |
RAB3IP |
RAB3A interacting protein |
increases expression |
EXP |
mocetinostat results in increased expression of RAB3IP mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:11,673,749...11,714,282
Ensembl chr10:11,673,777...11,714,281
|
|
G |
RABEPK |
Rab9 effector protein with kelch motifs |
increases expression |
EXP |
mocetinostat results in increased expression of RABEPK mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 9:57,857,269...57,877,333
Ensembl chr 9:57,857,269...57,883,761
|
|
G |
SCAMP3 |
secretory carrier membrane protein 3 |
decreases expression |
EXP |
mocetinostat results in decreased expression of SCAMP3 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 7:42,294,764...42,299,097
|
|
G |
SCN10A |
sodium voltage-gated channel alpha subunit 10 |
increases expression |
EXP |
mocetinostat results in increased expression of SCN10A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr23:8,420,468...8,527,414
Ensembl chr23:8,420,472...8,527,383
|
|
G |
SDCBP |
syndecan binding protein |
increases expression |
EXP |
mocetinostat results in increased expression of SDCBP mRNA |
CTD |
PMID:27255383 |
|
NCBI chr29:9,331,876...9,370,489
|
|
G |
SEC24B |
SEC24 homolog B, COPII coat complex component |
increases expression |
EXP |
mocetinostat results in increased expression of SEC24B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr32:29,671,702...29,766,628
Ensembl chr32:29,671,738...29,772,192
|
|
G |
SEC24D |
SEC24 homolog D, COPII coat complex component |
increases expression |
EXP |
mocetinostat results in increased expression of SEC24D mRNA |
CTD |
PMID:27255383 |
|
NCBI chr32:37,690,158...37,795,762
Ensembl chr32:37,690,399...37,924,252
|
|
G |
SEC63 |
SEC63 homolog, protein translocation regulator |
increases expression |
EXP |
mocetinostat results in increased expression of SEC63 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr12:64,983,442...65,028,573
|
|
G |
SFT2D1 |
SFT2 domain containing 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of SFT2D1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 1:54,335,832...54,354,199
Ensembl chr 1:54,336,005...54,354,137
|
|
G |
SMTN |
smoothelin |
decreases expression |
EXP |
mocetinostat results in decreased expression of SMTN mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:24,085,356...24,108,005
Ensembl chr26:24,085,382...24,108,540
|
|
G |
SNAP23 |
synaptosome associated protein 23 |
increases expression |
EXP |
mocetinostat results in increased expression of SNAP23 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr30:9,453,931...9,493,506
Ensembl chr30:9,456,084...9,492,329
|
|
G |
SNAPIN |
SNAP associated protein |
decreases expression |
EXP |
mocetinostat results in decreased expression of SNAPIN mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 7:43,410,554...43,411,929
Ensembl chr 7:43,410,998...43,412,323
|
|
G |
SNX15 |
sorting nexin 15 |
decreases expression |
EXP |
mocetinostat results in decreased expression of SNX15 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr18:52,152,562...52,165,081
Ensembl chr18:52,152,561...52,165,048
|
|
G |
SNX16 |
sorting nexin 16 |
increases expression |
EXP |
mocetinostat results in increased expression of SNX16 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr29:28,882,768...28,922,713
Ensembl chr29:28,884,426...28,920,797
|
|
G |
SNX17 |
sorting nexin 17 |
decreases expression |
EXP |
mocetinostat results in decreased expression of SNX17 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:21,326,496...21,332,170
Ensembl chr17:21,326,503...21,331,857
|
|
G |
SNX24 |
sorting nexin 24 |
increases expression |
EXP |
mocetinostat results in increased expression of SNX24 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr11:12,776,934...12,869,304
Ensembl chr11:12,708,712...12,888,165
|
|
G |
SNX7 |
sorting nexin 7 |
increases expression |
EXP |
mocetinostat results in increased expression of SNX7 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 6:51,004,307...51,388,283
Ensembl chr 6:51,025,203...51,094,539
|
|
G |
SPTBN1 |
spectrin beta, non-erythrocytic 1 |
increases expression |
EXP |
mocetinostat results in increased expression of SPTBN1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:55,429,989...55,571,917
Ensembl chr10:55,429,940...55,571,916
|
|
G |
STAM2 |
signal transducing adaptor molecule 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of STAM2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr19:53,213,904...53,256,711
Ensembl chr19:53,216,274...53,256,756 Ensembl chr19:53,216,274...53,256,756
|
|
G |
STON1 |
stonin 1 |
increases expression |
EXP |
mocetinostat results in increased expression of STON1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:50,421,635...50,470,302
Ensembl chr10:50,436,715...50,467,878
|
|
G |
STX4 |
syntaxin 4 |
decreases expression |
EXP |
mocetinostat results in decreased expression of STX4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 6:17,184,044...17,189,481
Ensembl chr 6:17,184,399...17,189,370
|
|
G |
SYTL1 |
synaptotagmin like 1 |
increases expression |
EXP |
mocetinostat results in increased expression of SYTL1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 2:72,916,445...72,925,219
Ensembl chr 2:72,916,445...72,925,147
|
|
G |
SYTL4 |
synaptotagmin like 4 |
increases expression |
EXP |
mocetinostat results in increased expression of SYTL4 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr X:74,537,937...74,617,580
Ensembl chr X:74,539,183...74,565,753
|
|
G |
TFRC |
transferrin receptor |
decreases expression |
EXP |
mocetinostat results in decreased expression of TFRC mRNA |
CTD |
PMID:27255383 |
|
NCBI chr33:29,206,024...29,237,221
Ensembl chr33:29,208,609...29,238,242
|
|
G |
TMED1 |
transmembrane p24 trafficking protein 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of TMED1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr20:50,395,862...50,399,118
Ensembl chr20:50,396,005...50,407,535
|
|
G |
TMED2 |
transmembrane p24 trafficking protein 2 |
decreases expression |
EXP |
mocetinostat results in decreased expression of TMED2 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:6,039,046...6,047,490
Ensembl chr26:6,039,405...6,047,459
|
|
G |
TRIM54 |
tripartite motif containing 54 |
decreases expression |
EXP |
mocetinostat results in decreased expression of TRIM54 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr17:21,257,660...21,278,410
Ensembl chr17:21,257,706...21,278,274
|
|
G |
TSG101 |
tumor susceptibility 101 |
decreases expression |
EXP |
mocetinostat results in decreased expression of TSG101 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr21:40,910,870...40,952,922
Ensembl chr21:40,910,874...40,952,808
|
|
G |
TTN |
titin |
decreases expression |
EXP |
mocetinostat results in decreased expression of TTN mRNA |
CTD |
PMID:27255383 |
|
NCBI chr36:22,146,870...22,417,858
Ensembl chr36:22,147,824...22,417,826
|
|
G |
TUBA4A |
tubulin alpha 4a |
decreases expression |
EXP |
mocetinostat results in decreased expression of TUBA4A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr37:25,799,075...25,803,257
Ensembl chr37:25,796,107...25,802,892
|
|
G |
TUBG1 |
tubulin, gamma 1 |
decreases expression |
EXP |
mocetinostat results in decreased expression of TUBG1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 9:20,358,683...20,363,455
Ensembl chr 9:20,322,253...20,363,455
|
|
G |
USO1 |
USO1 vesicle transport factor |
decreases expression |
EXP |
mocetinostat results in decreased expression of USO1 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr32:305,895...395,113
Ensembl chr32:305,935...394,896
|
|
G |
VPS13B |
vacuolar protein sorting 13 homolog B |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS13B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr13:1,101,226...1,834,933
Ensembl chr13:1,101,610...1,871,225
|
|
G |
VPS16 |
VPS16 core subunit of CORVET and HOPS complexes |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS16 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr24:18,401,440...18,424,605
Ensembl chr24:18,399,572...18,424,510
|
|
G |
VPS26A |
VPS26, retromer complex component A |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS26A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 4:20,265,120...20,296,125
Ensembl chr 4:20,264,905...20,294,674
|
|
G |
VPS29 |
VPS29 retromer complex component |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS29 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:8,301,699...8,309,364
Ensembl chr26:8,301,699...8,309,364
|
|
G |
VPS33A |
VPS33A core subunit of CORVET and HOPS complexes |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS33A mRNA |
CTD |
PMID:27255383 |
|
NCBI chr26:7,090,669...7,119,913
|
|
G |
VPS33B |
VPS33B late endosome and lysosome associated |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS33B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 3:53,220,199...53,239,738
Ensembl chr 3:53,220,194...53,239,732
|
|
G |
VPS35 |
VPS35 retromer complex component |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS35 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr15:8,428,073...8,454,601
Ensembl chr15:8,428,172...8,454,049
|
|
G |
VPS41 |
VPS41 subunit of HOPS complex |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS41 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr18:10,788,846...10,956,207
Ensembl chr18:10,788,891...10,955,645
|
|
G |
VPS52 |
VPS52 subunit of GARP complex |
decreases expression |
EXP |
mocetinostat results in decreased expression of VPS52 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr12:2,697,508...2,712,831
Ensembl chr12:2,697,508...2,712,831
|
|
G |
VPS54 |
VPS54 subunit of GARP complex |
increases expression |
EXP |
mocetinostat results in increased expression of VPS54 mRNA |
CTD |
PMID:27255383 |
|
NCBI chr10:63,598,373...63,676,753
Ensembl chr10:63,599,229...63,676,747
|
|
G |
VTI1B |
vesicle transport through interaction with t-SNAREs 1B |
decreases expression |
EXP |
mocetinostat results in decreased expression of VTI1B mRNA |
CTD |
PMID:27255383 |
|
NCBI chr 8:41,619,365...41,650,389
Ensembl chr29:19,153,616...19,154,245 Ensembl chr 8:19,153,616...19,154,245
|
|
|
G |
IL6 |
interleukin 6 |
multiple interactions decreases expression |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of IL6 protein] N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide results in decreased expression of IL6 protein |
CTD |
PMID:24105867 |
|
NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
|
|
G |
PRKACA |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Amphotericin B results in increased expression of PRKACG protein] |
CTD |
PMID:24105867 |
|
NCBI chr20:48,416,730...48,425,237
Ensembl chr20:48,409,045...48,426,669
|
|
|
G |
CLDN4 |
claudin 4 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased expression of CLDN4 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased expression of CLDN4 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:6,492,706...6,506,750
Ensembl chr 6:6,493,513...6,494,145
|
|
G |
MAPK1 |
mitogen-activated protein kinase 1 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:23816505 |
|
NCBI chr26:31,013,607...31,132,998
Ensembl chr26:31,013,607...31,132,998
|
|
G |
MAPK3 |
mitogen-activated protein kinase 3 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:23816505 |
|
NCBI chr 6:18,109,184...18,115,728
Ensembl chr 6:18,109,222...18,114,425
|
|
G |
MAPK8 |
mitogen-activated protein kinase 8 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK8 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:23816505 |
|
NCBI chr28:323,361...410,367
Ensembl chr28:368,513...406,401
|
|
G |
MAPK9 |
mitogen-activated protein kinase 9 |
multiple interactions |
EXP |
Acetylcysteine inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK9 protein]; Acetylcysteine inhibits the reaction [Sodium Chloride results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:23816505 |
|
NCBI chr11:1,443,528...1,480,501
Ensembl chr11:1,443,547...1,478,119
|
|
|
G |
GJA1 |
gap junction protein alpha 1 |
decreases expression |
EXP |
Dimethylnitrosamine results in decreased expression of GJA1 protein |
CTD |
PMID:15736408 |
|
NCBI chr 1:60,941,772...60,944,694
Ensembl chr 1:60,929,097...60,942,936
|
|
|
G |
ADRA1D |
adrenoceptor alpha 1D |
multiple interactions |
EXP |
naftopidil binds to and results in decreased activity of ADRA1D protein; naftopidil inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1D protein] |
CTD |
PMID:19371927 |
|
NCBI chr24:17,231,771...17,239,110
Ensembl chr24:17,213,643...17,214,761 Ensembl chr24:17,213,643...17,214,761
|
|
|
G |
POMC |
proopiomelanocortin |
increases expression |
EXP |
nalmefene results in increased expression of POMC protein alternative form |
CTD |
PMID:3026683 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
|
G |
POMC |
proopiomelanocortin |
increases expression |
EXP |
Naloxone results in increased expression of POMC protein |
CTD |
PMID:8277081 |
|
NCBI chr17:19,431,396...19,438,247
Ensembl chr17:19,431,585...19,434,440
|
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
affects expression increases expression |
EXP |
nefiracetam affects the expression of PTGS2 mRNA nefiracetam results in increased expression of PTGS2 protein |
CTD |
PMID:16105799 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
|
G |
PPARG |
peroxisome proliferator activated receptor gamma |
increases expression multiple interactions |
EXP |
Niacinamide results in increased expression of PPARG protein Resveratrol inhibits the reaction [Niacinamide results in increased expression of PPARG protein] |
CTD |
PMID:22539994 |
|
NCBI chr20:6,134,618...6,265,481
Ensembl chr20:6,050,357...6,207,981
|
|
G |
RUNX2 |
RUNX family transcription factor 2 |
increases acetylation multiple interactions decreases expression |
EXP |
Niacinamide results in increased acetylation of RUNX2 protein Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]; Resveratrol inhibits the reaction [Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]]; Resveratrol inhibits the reaction [Niacinamide results in decreased expression of RUNX2 protein]; Resveratrol inhibits the reaction [Niacinamide results in increased acetylation of RUNX2 protein] |
CTD |
PMID:22539994 |
|
NCBI chr12:13,723,535...13,842,565
Ensembl chr12:13,628,539...13,840,785 Ensembl chr12:13,628,539...13,840,785
|
|
G |
SIRT1 |
sirtuin 1 |
decreases expression multiple interactions |
EXP |
Niacinamide results in decreased expression of SIRT1 protein Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]; Resveratrol inhibits the reaction [Niacinamide inhibits the reaction [SIRT1 protein binds to RUNX2 protein]]; Resveratrol inhibits the reaction [Niacinamide results in decreased expression of SIRT1 protein] |
CTD |
PMID:22539994 |
|
NCBI chr 4:19,188,616...19,220,031
Ensembl chr 4:19,188,675...19,218,279
|
|
|
G |
IL1B |
interleukin 1 beta |
decreases expression |
EXP |
nimesulide results in decreased expression of IL1B mRNA |
CTD |
PMID:19638440 |
|
NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
nimesulide results in decreased expression of PTGS2 mRNA |
CTD |
PMID:15198222 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
|
G |
KNG1 |
kininogen 1 |
increases activity |
EXP |
Nitric Oxide deficiency results in increased activity of KNG1 protein modified form |
CTD |
PMID:10805402 |
|
NCBI chr34:19,288,629...19,318,096
Ensembl chr34:19,287,109...19,318,081
|
|
G |
WT1 |
WT1 transcription factor |
multiple interactions |
EXP |
[Nitroprusside results in increased abundance of Nitric Oxide] which results in increased expression of WT1 mRNA |
CTD |
PMID:21443142 |
|
NCBI chr18:35,099,660...35,148,767
Ensembl chr18:35,103,934...35,148,000
|
|
|
G |
KNG1 |
kininogen 1 |
increases chemical synthesis |
EXP |
KNG1 protein modified form results in increased chemical synthesis of Nitrites |
CTD |
PMID:17644579 |
|
NCBI chr34:19,288,629...19,318,096
Ensembl chr34:19,287,109...19,318,081
|
|
|
G |
REN |
renin |
decreases activity |
EXP |
Nitroglycerin results in decreased activity of REN protein |
CTD |
PMID:8640982 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
PTGS2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 mRNA; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased expression of PTGS2 protein |
CTD |
PMID:12857884 PMID:15198222 |
|
NCBI chr 7:19,668,079...19,674,903
Ensembl chr 7:19,668,082...19,674,903
|
|
G |
RELA |
RELA proto-oncogene, NF-kB subunit |
decreases localization |
EXP |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased localization of RELA protein |
CTD |
PMID:12857884 |
|
NCBI chr18:51,550,003...51,558,861
Ensembl chr18:51,550,040...51,558,875
|
|
|
G |
ACTA2 |
actin alpha 2, smooth muscle |
multiple interactions increases expression |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein] ochratoxin A results in increased expression of ACTA2 mRNA; ochratoxin A results in increased expression of ACTA2 protein |
CTD |
PMID:33543323 |
|
NCBI chr26:38,700,434...38,714,915
Ensembl chr26:38,700,480...38,711,753
|
|
G |
B9D2 |
B9 domain containing 2 |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of TGFB1 mRNA; ochratoxin A results in increased expression of TGFB1 protein CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein] |
CTD |
PMID:33543323 |
|
NCBI chr 1:112,621,832...112,627,726
Ensembl chr 1:112,621,633...112,643,885
|
|
G |
CASP4 |
caspase 4, apoptosis-related cysteine peptidase |
multiple interactions increases expression increases cleavage |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA] |
CTD |
PMID:33543323 |
|
NCBI chr 5:27,133,778...27,147,954
Ensembl chr 5:27,132,565...27,149,736
|
|
G |
GSDMD |
gasdermin D |
multiple interactions increases expression |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein] ochratoxin A results in increased expression of GSDMD mRNA; ochratoxin A results in increased expression of GSDMD protein |
CTD |
PMID:33543323 |
|
NCBI chr13:37,221,219...37,226,912
Ensembl chr13:37,193,022...37,228,360
|
|
G |
IL18 |
interleukin 18 |
multiple interactions increases expression |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA] |
CTD |
PMID:33543323 |
|
NCBI chr 5:20,972,742...20,995,327
Ensembl chr 5:20,972,871...20,995,348
|
|
G |
IL1B |
interleukin 1 beta |
multiple interactions increases expression |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein] ochratoxin A results in increased expression of IL1B mRNA; ochratoxin A results in increased expression of IL1B protein |
CTD |
PMID:33543323 |
|
NCBI chr17:37,019,329...37,033,388
Ensembl chr17:37,019,329...37,024,458
|
|
G |
IL6 |
interleukin 6 |
increases secretion increases expression |
EXP |
ochratoxin A results in increased secretion of IL6 protein ochratoxin A results in increased expression of IL6 mRNA |
CTD |
PMID:33543323 |
|
NCBI chr14:36,474,268...36,478,519
Ensembl chr14:36,473,394...36,478,519
|
|
G |
NLRP3 |
NLR family pyrin domain containing 3 |
multiple interactions increases expression |
EXP |
N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of NLRP3 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased cleavage of CASP1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of ACTA2 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of CASP1 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of GSDMD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL18 mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of IL1B protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of TGFB1 protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of NLRP3 mRNA; ochratoxin A results in increased expression of NLRP3 protein |
CTD |
PMID:33543323 |
|
NCBI chr 8:251,776...313,290
Ensembl chr 8:253,407...313,059
|
|
G |
PYCARD |
PYD and CARD domain containing |
increases expression multiple interactions |
EXP |
ochratoxin A results in increased expression of PYCARD mRNA; ochratoxin A results in increased expression of PYCARD protein N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of PYCARD protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD mRNA]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of PYCARD protein] |
CTD |
PMID:33543323 |
|
NCBI chr 6:17,049,352...17,051,348
Ensembl chr 6:17,049,705...17,051,240
|
|
G |
TNF |
tumor necrosis factor |
increases secretion increases expression |
EXP |
ochratoxin A results in increased secretion of TNF protein ochratoxin A results in increased expression of TNF mRNA |
CTD |
PMID:33543323 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
G |
VIM |
vimentin |
multiple interactions increases expression |
EXP |
CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM mRNA]; CASP1 protein affects the reaction [ochratoxin A results in increased expression of VIM protein]; N-(1,2,3,5,6,7-hexahydro-S-indacen-4-ylcarbamoyl)-4-(2-hydroxy-2-propanyl)-2-furansulfonamide inhibits the reaction [ochratoxin A results in increased expression of VIM protein]; NLRP3 protein affects the reaction [ochratoxin A results in increased expression of VIM protein] ochratoxin A results in increased expression of VIM mRNA; ochratoxin A results in increased expression of VIM protein |
CTD |
PMID:33543323 |
|
NCBI chr 2:19,671,316...19,679,367
Ensembl chr 2:19,671,316...19,679,466
|
|
|
G |
CAPN1 |
calpain 1 |
increases expression |
EXP |
Ofloxacin results in increased expression of CAPN1 mRNA |
CTD |
PMID:24582689 |
|
NCBI chr18:51,983,266...52,010,831
Ensembl chr18:51,983,824...52,010,757
|
|
G |
CASP12 |
caspase 12 |
increases expression |
EXP |
Ofloxacin results in increased expression of CASP12 mRNA; Ofloxacin results in increased expression of CASP12 protein |
CTD |
PMID:24582689 |
|
NCBI chr 5:27,162,840...27,176,964
Ensembl chr 5:27,161,700...27,177,683
|
|
G |
CASP8 |
caspase 8 |
multiple interactions increases expression |
EXP |
TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of CASP8 mRNA] |
CTD |
PMID:24582689 |
|
NCBI chr37:10,362,071...10,402,108
Ensembl chr37:10,391,048...10,401,822
|
|
G |
DDIT3 |
DNA damage inducible transcript 3 |
increases expression |
EXP |
Ofloxacin results in increased expression of DDIT3 mRNA |
CTD |
PMID:24582689 |
|
NCBI chr10:1,606,693...1,612,410
Ensembl chr10:1,606,693...1,611,303
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Ofloxacin results in increased expression of HSPA5 mRNA |
CTD |
PMID:24582689 |
|
NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
|
|
G |
TNF |
tumor necrosis factor |
increases expression |
EXP |
Ofloxacin results in increased expression of TNF mRNA; Ofloxacin results in increased expression of TNF protein |
CTD |
PMID:24582689 |
|
NCBI chr12:1,074,561...1,076,425
Ensembl chr12:1,074,552...1,076,425
|
|
G |
TNFRSF1A |
TNF receptor superfamily member 1A |
multiple interactions increases expression |
EXP |
TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of CASP8 mRNA]; TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of TRADD mRNA] Ofloxacin results in increased expression of TNFRSF1A mRNA; Ofloxacin results in increased expression of TNFRSF1A protein |
CTD |
PMID:24582689 |
|
NCBI chr27:38,641,837...38,654,693
Ensembl chr27:38,638,753...38,700,282
|
|
G |
TRADD |
TNFRSF1A associated via death domain |
multiple interactions increases expression |
EXP |
TNFRSF1A mutant form inhibits the reaction [Ofloxacin results in increased expression of TRADD mRNA] |
CTD |
PMID:24582689 |
|
NCBI chr 5:82,200,430...82,211,430
Ensembl chr 5:82,206,111...82,210,963
|
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Omeprazole results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Omeprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
SLC22A6 |
solute carrier family 22 member 6 |
multiple interactions |
EXP |
[Pantoprazole results in decreased activity of SLC22A6 protein] which results in decreased uptake of Indican |
CTD |
PMID:36243147 |
|
NCBI chr18:53,736,669...53,745,001
Ensembl chr18:53,736,959...53,744,396
|
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Acetaminophen results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
G |
UGT1A6 |
UDP glucuronosyltransferase 1 family, polypeptide A6 |
increases glucuronidation |
EXP |
UGT1A6 protein results in increased glucuronidation of Acetaminophen |
CTD |
PMID:11903872 |
|
NCBI chr25:45,081,655...45,161,584
Ensembl chr25:45,032,130...45,160,941
|
|
|
G |
SLC22A2 |
solute carrier family 22 member 2 |
decreases activity |
EXP |
penconazole results in decreased activity of SLC22A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 1:49,327,621...49,348,435
Ensembl chr 1:49,327,296...49,348,435
|
|
G |
SLC22A5 |
solute carrier family 22 member 5 |
decreases activity |
EXP |
penconazole results in decreased activity of SLC22A5 protein |
CTD |
PMID:36669674 |
|
NCBI chr11:20,659,023...20,686,359
Ensembl chr11:20,598,888...20,683,087
|
|
G |
SLC47A1 |
solute carrier family 47 member 1 |
decreases activity |
EXP |
penconazole results in decreased activity of SLC47A1 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,643,420...40,679,130
Ensembl chr 5:40,642,784...40,679,946
|
|
G |
SLC47A2 |
solute carrier family 47 member 2 |
decreases activity |
EXP |
penconazole results in decreased activity of SLC47A2 protein |
CTD |
PMID:36669674 |
|
NCBI chr 5:40,491,306...40,515,430
Ensembl chr 5:40,491,933...40,540,136
|
|
|
G |
REN |
renin |
increases activity |
EXP |
Pentobarbital results in increased activity of REN protein |
CTD |
PMID:6348358 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
TJP1 |
tight junction protein 1 |
multiple interactions |
EXP |
Phalloidine inhibits the reaction [Calcium Oxalate results in decreased expression of TJP1 protein] |
CTD |
PMID:34147488 |
|
NCBI chr 3:38,997,122...39,076,617
Ensembl chr 3:38,997,076...39,241,574
|
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
affects metabolic processing |
EXP |
CYP1A2 protein affects the metabolism of Phenacetin |
CTD |
PMID:15801540 |
|
NCBI chr30:37,818,400...37,824,192
Ensembl chr30:37,799,140...37,824,135
|
|
G |
PTGS1 |
prostaglandin-endoperoxide synthase 1 |
decreases activity |
EXP |
Phenacetin results in decreased activity of PTGS1 protein alternative form |
CTD |
PMID:12242329 |
|
NCBI chr 9:60,195,118...60,216,847
Ensembl chr 9:60,195,124...60,216,819
|
|
|
G |
ACAA1 |
acetyl-CoA acyltransferase 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of ACAA1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr23:7,889,481...7,901,324
Ensembl chr23:7,889,500...7,901,229
|
|
G |
ACAA2 |
acetyl-CoA acyltransferase 2 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of ACAA2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 7:79,028,636...79,057,720
|
|
G |
ACOX2 |
acyl-CoA oxidase 2 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of ACOX2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr20:32,110,788...32,141,751
Ensembl chr20:32,113,217...32,141,734
|
|
G |
AGXT |
alanine--glyoxylate and serine--pyruvate aminotransferase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of AGXT protein |
CTD |
PMID:19952500 |
|
NCBI chr25:50,968,291...50,976,089
|
|
G |
AHCY |
adenosylhomocysteinase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of AHCY protein |
CTD |
PMID:19952500 |
|
NCBI chr24:23,410,553...23,423,494
Ensembl chr24:23,411,140...23,419,767
|
|
G |
ASL |
argininosuccinate lyase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of ASL protein |
CTD |
PMID:19952500 |
|
NCBI chr 6:768,522...779,144
Ensembl chr 6:730,358...779,424
|
|
G |
ASS1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of ASS1 protein |
CTD |
PMID:19952500 |
|
NCBI chr 9:53,425,228...53,478,007
Ensembl chr 9:53,425,448...53,477,904
|
|
G |
BHMT |
betaine--homocysteine S-methyltransferase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of BHMT protein |
CTD |
PMID:19952500 |
|
NCBI chr 3:27,732,381...27,752,168
Ensembl chr 3:27,734,108...27,752,046
|
|
G |
CA3 |
carbonic anhydrase 3 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CA3 protein |
CTD |
PMID:19952500 |
|
NCBI chr29:31,935,192...31,945,585
Ensembl chr29:31,935,172...31,980,579
|
|
G |
CPT1A |
carnitine palmitoyltransferase 1A |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CPT1A mRNA |
CTD |
PMID:19952500 |
|
NCBI chr18:49,136,691...49,190,117
Ensembl chr18:49,136,691...49,190,117
|
|
G |
CRYZ |
crystallin zeta |
increases expression |
EXP |
Phenobarbital results in increased expression of CRYZ protein |
CTD |
PMID:19952500 |
|
NCBI chr 6:71,656,162...71,693,020
Ensembl chr 6:71,656,188...71,675,692
|
|
G |
CYP1A2 |
cytochrome P450 family 1 subfamily A member 2 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CYP1A2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr30:37,818,400...37,824,192
Ensembl chr30:37,799,140...37,824,135
|
|
G |
CYP2A13 |
cytochrome P450 family 2 subfamily A polypeptide 13 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CYP2A13 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 1:112,932,246...112,938,248
Ensembl chr 1:112,931,985...112,938,350
|
|
G |
CYP2B6 |
cytochrome P450 2B11 |
increases expression |
EXP |
Phenobarbital results in increased expression of CYP2B6 protein |
CTD |
PMID:19952500 |
|
NCBI chr 1:112,817,561...112,833,294
Ensembl chr 1:112,816,502...112,833,293
|
|
G |
CYP2E1 |
cytochrome P450 family 2 subfamily E member 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr28:41,079,164...41,089,188
Ensembl chr28:41,035,025...41,122,754
|
|
G |
CYP3A12 |
cytochrome P-450 3A12 |
increases expression |
EXP |
Phenobarbital results in increased expression of CYP3A12 protein |
CTD |
PMID:19952500 |
|
|
|
G |
CYP3A26 |
cytochrome P450 3A26 |
increases expression |
EXP |
Phenobarbital results in increased expression of CYP3A26 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 6:9,777,663...9,815,345
Ensembl chr 6:9,777,659...9,869,352
|
|
G |
CYP3A4 |
cytochrome P450, family 3, subfamily A, polypeptide 4 |
increases expression |
EXP |
Phenobarbital results in increased expression of CYP3A4 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr 6:9,836,685...9,869,520
Ensembl chr 6:9,777,659...9,869,352
|
|
G |
CYP4A37 |
cytochrome P450 4A37 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of CYP4A11 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr15:13,604,130...13,623,797
|
|
G |
EHHADH |
enoyl-CoA hydratase and 3-hydroxyacyl CoA dehydrogenase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of EHHADH mRNA |
CTD |
PMID:19952500 |
|
NCBI chr34:18,021,047...18,080,993
Ensembl chr34:18,022,353...18,080,903
|
|
G |
FTCD |
formimidoyltransferase cyclodeaminase |
increases expression |
EXP |
Phenobarbital results in increased expression of FTCD protein |
CTD |
PMID:19952500 |
|
NCBI chr31:39,451,557...39,464,249
Ensembl chr31:39,275,159...39,464,715
|
|
G |
GOT1 |
glutamic-oxaloacetic transaminase 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of GOT1 protein |
CTD |
PMID:19952500 |
|
NCBI chr28:12,352,658...12,377,960
Ensembl chr28:12,352,659...12,414,579
|
|
G |
GSTA4 |
glutathione S-transferase alpha 4 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of GSTA4 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr12:20,426,724...20,443,200
Ensembl chr12:20,426,726...20,443,200
|
|
G |
GSTO1 |
glutathione S-transferase omega 1 |
increases expression |
EXP |
Phenobarbital results in increased expression of GSTO1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr28:16,569,421...16,579,239
Ensembl chr28:16,569,066...16,619,880
|
|
G |
GSTT2B |
glutathione S-transferase theta 2B |
decreases expression |
EXP |
Phenobarbital results in decreased expression of GSTT2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr26:28,573,435...28,580,846
|
|
G |
HADH |
hydroxyacyl-CoA dehydrogenase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of HADH mRNA |
CTD |
PMID:19952500 |
|
NCBI chr32:28,460,445...28,506,141
Ensembl chr32:28,460,193...28,531,280
|
|
G |
HPD |
4-hydroxyphenylpyruvate dioxygenase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of HPD protein |
CTD |
PMID:19952500 |
|
NCBI chr26:7,430,891...7,440,643
Ensembl chr26:7,430,933...7,440,611
|
|
G |
HSPA5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Phenobarbital results in increased expression of HSPA5 protein |
CTD |
PMID:19952500 |
|
NCBI chr 9:57,850,870...57,855,607
Ensembl chr 9:57,850,922...57,855,257
|
|
G |
IDH1 |
isocitrate dehydrogenase (NADP(+)) 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of IDH1 protein |
CTD |
PMID:19952500 |
|
NCBI chr37:16,512,027...16,531,269
Ensembl chr37:16,512,770...16,531,219
|
|
G |
LOC474938 |
glutathione S-transferase A2 |
increases expression |
EXP |
Phenobarbital results in increased expression of GSTA3 protein |
CTD |
PMID:19952500 |
|
NCBI chr12:20,349,133...20,365,023
|
|
G |
LOC477540 |
SEC14-like protein 3 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of SEC14L3 protein |
CTD |
PMID:19952500 |
|
NCBI chr26:23,580,899...23,590,676
Ensembl chr26:23,580,901...23,590,622
|
|
G |
LOC486353 |
SEC14-like protein 4 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of SEC14L4 protein |
CTD |
PMID:19952500 |
|
NCBI chr26:23,598,434...23,611,727
Ensembl chr26:23,600,237...23,618,123
|
|
G |
MGST1 |
microsomal glutathione S-transferase 1 |
increases expression |
EXP |
Phenobarbital results in increased expression of MGST1 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr27:30,370,588...30,391,898
Ensembl chr27:30,370,594...30,391,778
|
|
G |
MGST2 |
microsomal glutathione S-transferase 2 |
increases expression |
EXP |
Phenobarbital results in increased expression of MGST2 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr19:3,067,062...3,070,579
|
|
G |
MGST3 |
microsomal glutathione S-transferase 3 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of MGST3 mRNA |
CTD |
PMID:19952500 |
|
NCBI chr38:17,670,329...17,691,822
Ensembl chr38:17,668,752...17,718,704
|
|
G |
PAH |
phenylalanine hydroxylase |
decreases expression |
EXP |
Phenobarbital results in decreased expression of PAH protein |
CTD |
PMID:19952500 |
|
NCBI chr15:41,590,253...41,670,156
Ensembl chr15:41,592,876...41,670,837
|
|
G |
PDIA3 |
protein disulfide isomerase family A member 3 |
increases expression |
EXP |
Phenobarbital results in increased expression of PDIA3 protein |
CTD |
PMID:19952500 |
|
NCBI chr30:10,487,926...10,513,437
Ensembl chr30:10,487,921...10,513,397
|
|
G |
PRDX6 |
peroxiredoxin 6 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of PRDX6 protein |
CTD |
PMID:19952500 |
|
NCBI chr 7:25,663,238...25,675,855
Ensembl chr 7:25,663,579...25,675,754
|
|
G |
SELENBP1 |
selenium binding protein 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of SELENBP1 protein |
CTD |
PMID:19952500 |
|
NCBI chr17:60,410,727...60,418,770
Ensembl chr17:60,410,734...60,418,704
|
|
G |
SOD1 |
superoxide dismutase 1 |
affects response to substance |
EXP |
SOD1 protein affects the susceptibility to Phenobarbital |
CTD |
PMID:6333936 |
|
NCBI chr31:26,540,291...26,544,212
Ensembl chr31:26,486,274...26,662,815
|
|
G |
UGDH |
UDP-glucose 6-dehydrogenase |
increases expression |
EXP |
Phenobarbital results in increased expression of UGDH protein |
CTD |
PMID:19952500 |
|
NCBI chr 3:72,935,532...72,964,151
Ensembl chr 3:72,839,920...72,963,208
|
|
G |
UGT2B31 |
UDP-glucuronosyltransferase UGT2B31 |
increases expression |
EXP |
Phenobarbital results in increased expression of UGT2B4 protein |
CTD |
PMID:19952500 |
|
NCBI chr13:58,993,957...59,007,420
|
|
G |
UROC1 |
urocanate hydratase 1 |
decreases expression |
EXP |
Phenobarbital results in decreased expression of UROC1 protein |
CTD |
PMID:19952500 |
|
NCBI chr20:676,624...717,109
Ensembl chr20:678,073...717,141
|
|
|
G |
ADRA1A |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
Phenylephrine binds to and results in increased activity of ADRA1A protein; silodosin inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1A protein] |
CTD |
PMID:19371927 |
|
NCBI chr25:30,690,959...30,801,484
Ensembl chr25:30,693,571...30,801,486
|
|
G |
ADRA1D |
adrenoceptor alpha 1D |
multiple interactions |
EXP |
BMY 7378 inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1D protein]; naftopidil inhibits the reaction [Phenylephrine binds to and results in increased activity of ADRA1D protein]; Phenylephrine binds to and results in increased activity of ADRA1D protein |
CTD |
PMID:19371927 |
|
NCBI chr24:17,231,771...17,239,110
Ensembl chr24:17,213,643...17,214,761 Ensembl chr24:17,213,643...17,214,761
|
|
G |
REN |
renin |
increases secretion |
EXP |
Phenylephrine results in increased secretion of REN protein |
CTD |
PMID:6347479 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
REN |
renin |
multiple interactions |
EXP |
Pindolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] |
CTD |
PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
NCF1 |
neutrophil cytosolic factor 1 |
decreases expression |
EXP |
pitavastatin results in decreased expression of NCF1 mRNA |
CTD |
PMID:15502390 |
|
NCBI chr 6:5,702,222...5,719,515
Ensembl chr 6:5,605,694...5,719,458
|
|
G |
NOS3 |
nitric oxide synthase 3 |
increases activity increases expression |
EXP |
pitavastatin results in increased activity of NOS3 protein pitavastatin results in increased expression of NOS3 mRNA |
CTD |
PMID:15502390 |
|
NCBI chr16:15,054,196...15,072,454
Ensembl chr16:15,011,344...15,072,277
|
|
G |
NOX4 |
NADPH oxidase 4 |
decreases expression |
EXP |
pitavastatin results in decreased expression of NOX4 mRNA |
CTD |
PMID:15502390 |
|
NCBI chr21:10,615,153...10,782,927
Ensembl chr21:10,615,970...10,775,277
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
[2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz |
CTD |
PMID:24389113 |
|
NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
|
|
G |
CYP1A1 |
cytochrome P450 family 1 subfamily A member 1 |
multiple interactions |
EXP |
[prochloraz binds to and results in increased activity of AHR protein] which results in increased activity of CYP1A1 protein |
CTD |
PMID:24389113 |
|
NCBI chr30:37,793,277...37,799,535
Ensembl chr30:37,793,508...37,796,866
|
|
|
G |
ADRB2 |
adrenoceptor beta 2 |
multiple interactions |
EXP |
[Propranolol binds to and results in decreased activity of ADRB2 protein] which results in decreased secretion of Norepinephrine |
CTD |
PMID:2884805 |
|
NCBI chr 4:60,048,502...60,050,447
Ensembl chr 4:59,941,517...60,050,298
|
|
G |
NPPA |
natriuretic peptide A |
increases expression |
EXP |
Propranolol results in increased expression of NPPA protein |
CTD |
PMID:2566282 |
|
NCBI chr 2:84,406,317...84,408,115
Ensembl chr 2:84,396,073...84,408,385
|
|
G |
REN |
renin |
multiple interactions decreases activity |
EXP |
Propranolol inhibits the reaction [Isoproterenol results in increased activity of REN protein] Propranolol results in decreased activity of REN protein |
CTD |
PMID:2566282 PMID:6103674 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
G |
VIP |
vasoactive intestinal peptide |
decreases expression |
EXP |
Propranolol results in decreased expression of VIP protein |
CTD |
PMID:2566282 |
|
NCBI chr 1:42,941,655...42,950,160
Ensembl chr 1:42,941,224...42,950,700
|
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Pyridines analog binds to and results in decreased activity of DRD2 protein |
CTD |
PMID:12593651 |
|
NCBI chr 5:19,732,842...19,795,241
Ensembl chr 5:19,732,836...19,795,241
|
|
|
G |
HEXB |
hexosaminidase subunit beta |
multiple interactions |
EXP |
Quinacrine promotes the reaction [mastoparan results in increased secretion of HEXB protein] |
CTD |
PMID:21671308 |
|
NCBI chr 2:57,221,809...57,248,432
Ensembl chr 2:57,222,186...57,248,417
|
|
|
G |
ATP2A2 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2 |
affects expression multiple interactions |
EXP |
Ranolazine affects the expression of ATP2A2 protein [Ranolazine co-treated with Enalapril] affects the expression of ATP2A2 protein; [Ranolazine co-treated with Metoprolol] affects the expression of ATP2A2 protein |
CTD |
PMID:18820026 |
|
NCBI chr26:8,148,181...8,209,392
Ensembl chr26:8,148,236...8,209,388
|
|
G |
EGR1 |
early growth response 1 |
multiple interactions affects expression |
EXP |
[Ranolazine co-treated with Enalapril] affects the expression of EGR1 protein; [Ranolazine co-treated with Metoprolol] affects the expression of EGR1 protein Ranolazine affects the expression of EGR1 protein |
CTD |
PMID:18820026 |
|
NCBI chr11:26,046,195...26,049,806
Ensembl chr11:26,046,228...26,048,575
|
|
G |
GATA4 |
GATA binding protein 4 |
affects expression multiple interactions |
EXP |
Ranolazine affects the expression of GATA4 protein [Ranolazine co-treated with Enalapril] affects the expression of GATA4 protein; [Ranolazine co-treated with Metoprolol] affects the expression of GATA4 protein |
CTD |
PMID:18820026 |
|
NCBI chr25:26,126,172...26,211,474
Ensembl chr25:26,127,853...26,182,989
|
|
G |
NAB1 |
NGFI-A binding protein 1 |
affects expression multiple interactions |
EXP |
Ranolazine affects the expression of NAB1 protein [Ranolazine co-treated with Enalapril] affects the expression of NAB1 protein; [Ranolazine co-treated with Metoprolol] affects the expression of NAB1 protein |
CTD |
PMID:18820026 |
|
NCBI chr37:1,207,619...1,243,546
Ensembl chr37:1,207,638...1,241,610
|
|
G |
SLC8A1 |
solute carrier family 8 member A1 |
affects expression multiple interactions |
EXP |
Ranolazine affects the expression of SLC8A1 protein [Ranolazine co-treated with Enalapril] affects the expression of SLC8A1 protein; [Ranolazine co-treated with Metoprolol] affects the expression of SLC8A1 protein |
CTD |
PMID:18820026 |
|
NCBI chr17:32,004,207...32,381,399
Ensembl chr17:32,005,245...32,307,700
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
increases expression |
EXP |
Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein |
CTD |
PMID:22620706 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Rifampin results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
|
G |
REN |
renin |
decreases activity |
EXP |
Rilmenidine results in decreased activity of REN protein |
CTD |
PMID:2866274 |
|
NCBI chr38:744,540...766,998
Ensembl chr38:744,614...755,012
|
|
|
G |
DRD2 |
dopamine receptor D2 |
multiple interactions |
EXP |
Risperidone binds to and results in decreased activity of DRD2 protein |
CTD |
PMID:16948927 |
|
NCBI chr 5:19,732,842...19,795,241
Ensembl chr 5:19,732,836...19,795,241
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
allicin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; hypericin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; kaempferol inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir]; Quercetin inhibits the reaction [ABCB1 protein results in increased secretion of Ritonavir] |
CTD |
PMID:15266218 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
G |
NR1I2 |
nuclear receptor subfamily 1 group I member 2 |
increases activity |
EXP |
Ritonavir results in increased activity of NR1I2 protein |
CTD |
PMID:27732639 |
|
NCBI chr33:23,444,367...23,456,405
Ensembl chr33:23,432,690...23,455,347
|
|
|
G |
AHR |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
[salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to prochloraz; [salicylamide binds to and results in decreased activity of AHR protein] which results in decreased susceptibility to Tetrachlorodibenzodioxin |
CTD |
PMID:24389113 |
|
NCBI chr14:31,743,704...31,793,484
Ensembl chr14:31,686,170...31,791,444
|
|
|
G |
ABCC2 |
ATP binding cassette subfamily C member 2 |
affects transport |
EXP |
ABCC2 protein affects the transport of Saquinavir |
CTD |
PMID:12702717 |
|
NCBI chr28:12,670,885...12,740,124
Ensembl chr28:12,670,885...12,740,740
|
|
|
G |
ABCB1 |
ATP binding cassette subfamily B member 1 |
multiple interactions |
EXP |
valspodar inhibits the reaction [ABCB1 protein affects the susceptibility to Doxorubicin]; valspodar inhibits the reaction [ABCB1 protein affects the susceptibility to Vincristine]; valspodar inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin] |
CTD |
PMID:15492788 PMID:24975508 |
|
NCBI chr14:13,644,891...13,852,829
Ensembl chr14:13,542,647...13,742,727
|
|
|
|